var title_f31_56_32640="Anterior shoulder dislocation";
var content_f31_56_32640=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F78276&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F78276&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Anterior shoulder dislocation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 421px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anteroposterior view of the right shoulder demonstrates medial displacement of the humeral head in relation to the glenoid fossa, with the humeral head lying inferior to the coracoid process.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cecilia M Jude, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_56_32640=[""].join("\n");
var outline_f31_56_32640=null;
var title_f31_56_32641="Functional reach test";
var content_f31_56_32641=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F54071&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F54071&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diagram of functional reach test to assess balance in elderly persons",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 413px; height: 399px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Subject stands with fist extended alongside a wall. Subject leans forward as far as possible, moving fist along wall without taking a step or losing stability. Length of fist movement is measured. Distances of less than 6 in (15 cm) indicate an increased risk of falling.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fleming KC, Evand JM, Weber DC, Chutka DS. Practical Functional Assessment of Elderly Persons: A Primary-Care Approach [Symposium on Geriatrics-Part III]. Mayo Clinic Proceedings 1995; 70:890. Copyright &copy; 1995 Mayo Foundation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_56_32641=[""].join("\n");
var outline_f31_56_32641=null;
var title_f31_56_32642="Posterior acetabular and femoral head fractures";
var content_f31_56_32642=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F50887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F50887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Posterior acetabular and femoral head fractures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 447px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) AP view. B) Right iliac oblique view illustrating posterior column and anterior wall. C) Right obturator oblique view demonstrating the anterior column and posterior wall fracture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jim Fiechtl, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_56_32642=[""].join("\n");
var outline_f31_56_32642=null;
var title_f31_56_32643="OraQuick rapid test";
var content_f31_56_32643=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F51525&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F51525&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    OraQuick rapid HIV-antibody test of oral fluids",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 380px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_56_32643=[""].join("\n");
var outline_f31_56_32643=null;
var title_f31_56_32644="Pathophysiology of V cholerae";
var content_f31_56_32644=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F69278&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F69278&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pathophysiology of vibrio cholerae infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 415px; height: 467px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representations of the mechanisms involved in diarrhea production by Vibrio cholerae.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from Butterton JR, Calderwood SB. Vibrio cholerae O1. In: Infections of the Gastrointestinal Tract, Blaser MJ, Smith PD, Ravdin Ll, et al (Eds), Raven Press, New York, 1995, p. 649.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_56_32644=[""].join("\n");
var outline_f31_56_32644=null;
var title_f31_56_32645="Development external genitalia";
var content_f31_56_32645=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F65480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F65480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 517px\">",
"   <div class=\"ttl\">",
"    Phenotypic differentiation of the external genitalia in female and male embryos",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 497px; height: 581px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In females, the genital tubercle becomes the clitoris, the genital swellings become the labia majora, and the genital folds become the labia minora. In males, the genital tubercle becomes the glans penis, the genital swellings fuse to become the scrotum, the genital folds elongate and fuse to form the shaft of the penis and the penile urethra, and the prostate forms in the wall of the urogenital sinus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_56_32645=[""].join("\n");
var outline_f31_56_32645=null;
var title_f31_56_32646="Tubal pregnancy adnexal mass";
var content_f31_56_32646=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53149&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53149&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tubal pregnancy as adnexal mass",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 515px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two examples of ectopic pregnancy presenting as an extraovarian adnexal mass (arrows).",
"    <div class=\"footnotes\">",
"     U: uterus; O: ovary.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tejas S Mehta, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_56_32646=[""].join("\n");
var outline_f31_56_32646=null;
var title_f31_56_32647="Sensory neuronopathy histopathology";
var content_f31_56_32647=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F65517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F65517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dorsal root ganglia in paraneoplastic sensory neuronopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 247px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of dorsal root ganglia from a patient with small cell lung cancer, anti-Hu antibodies, and paraneoplastic sensory neuronopathy. There are conspicuous infiltrates of mononuclear cells (small dark arrow), with some neurons undergoing degeneration (large dark arrow). There is also proliferation of satellite cells replacing the disappearing neurons, called Nageotte nodules (white arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Josep Dalmau, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_56_32647=[""].join("\n");
var outline_f31_56_32647=null;
var title_f31_56_32648="Dalteparin: Drug information";
var content_f31_56_32648=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dalteparin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/17/2325?source=see_link\">",
"    see \"Dalteparin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F156480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fragmin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F156481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Fragmin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F156518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Low Molecular Weight Heparin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F156483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Each 2500 units of anti-Xa activity is equal to 16 mg of dalteparin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Anticoagulant for hemodialysis and hemofiltration:",
"     </b>",
"     I.V.: Canadian labeling (not in U.S. labeling):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Chronic renal failure with no other bleeding risks:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Hemodialysis/filtration &le;4 hours: I.V. bolus: 5,000 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Hemodialysis/filtration &gt;4 hours: I.V. bolus: 30-40 units/kg, followed by an infusion of 10-15 units/kg/hour (typically produces plasma concentrations of 0.5-1 units anti-Xa/mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Acute renal failure and high bleeding risk: I.V. bolus: 5-10 units/kg, followed by an infusion of 4-5 units/kg/hour (typically produces plasma concentrations of 0.2-0.4 units anti-Xa/mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      DVT prophylaxis: Note:",
"     </b>",
"     In morbidly obese patients (BMI &ge;40 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ), increasing the prophylactic dose by 30% may be appropriate (Nutescu, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Abdominal surgery:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Low-to-moderate DVT risk:",
"     </i>",
"     SubQ: 2500 units 1-2 hours prior to surgery, then once daily for 5-10 days postoperatively",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      High DVT risk:",
"     </i>",
"     SubQ: 5000 units the evening prior to surgery and then once daily for 5-10 days postoperatively. Alternatively in patients with malignancy: 2500 units 1-2 hours prior to surgery, 2500 units 12 hours later, then 5000 units once daily for 5-10 days postoperatively.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      General surgery with risk factors for VTE: Canadian labeling (not in U.S. labeling):",
"     </b>",
"     2500 units 1-2 hours preoperatively followed by 2500-5000 int.units every morning (may administer 2500 units no sooner than 4 hours after surgery and 8 hours after previous dose provided hemostasis has been achieved) or if other risk factors are present (eg, malignancy, heart failure), then may administer 5000 units the evening prior to surgery followed by 5000 units every evening postoperatively; continue treatment until patient is mobilized (approximately &ge;5-7 days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Total hip replacement surgery:",
"     </b>",
"     SubQ:",
"     <b>",
"      Note:",
"     </b>",
"     Three treatment options are currently available. Dose is given for 5-10 days, although up to 14 days of treatment have been tolerated in clinical trials. The American College of Chest Physicians (ACCP) recommends a minimum duration of at least 10-14 days; extended duration of up to 35 days is suggested (Guyatt, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Postoperative regimen:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Initial: 2500 units 4-8 hours after surgery (or later if hemostasis not achieved). The ACCP recommends initiation &ge;12 hours after surgery if postoperative regimen chosen (Guyatt, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Maintenance: 5000 int. units once daily; allow at least 6 hours to elapse after initial postsurgical dose (adjust administration time accordingly)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Preoperative regimen (starting day of surgery):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Initial: 2500 int. units within 2 hours",
"     <b>",
"      before",
"     </b>",
"     surgery. The ACCP recommends initiation &ge;12 hours before surgery if preoperative regimen chosen (Guyatt, 2012). At 4-8 hours",
"     <b>",
"      after",
"     </b>",
"     surgery (or later if hemostasis not achieved), administer 2500 int. units.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Maintenance: 5000 units once daily; allow at least 6 hours to elpase after initial postsurgical dose (adjust administration time accordingly)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Preoperative regimen (starting evening prior to surgery):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Initial: 5000 int. units 10-14 hours",
"     <b>",
"      before",
"     </b>",
"     surgery. The ACCP recommends initiation &ge;12 hours before surgery if preoperative regimen chosen (Guyatt, 2012). At 4-8 hours",
"     <b>",
"      after",
"     </b>",
"     surgery (or later if hemostasis not achieved), administer 5000 int. units.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Maintenance: 5000 int. units once daily, allowing 24 hours between doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Immobility during acute illness:",
"     </b>",
"     5000 units once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Unstable angina or non-Q-wave myocardial infarction:",
"     </b>",
"     SubQ: 120 units/kg body weight (maximum dose: 10,000 units) every 12 hours for up to 5-8 days with concurrent aspirin therapy. Discontinue dalteparin once patient is clinically stable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Obesity:",
"     </i>",
"     Use actual body weight to calculate dose; dose capping at 10,000 units recommended (Nutescu, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Venous thromboembolism, extended treatment in cancer patients:",
"     </b>",
"     SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Initial (month 1): 200 units/kg (maximum dose: 18,000 units) once daily for 30 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Maintenance (months 2-6): ~150 units/kg (maximum dose: 18,000 units) once daily. If platelet count between 50,000-100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , reduce dose by 2,500 units until platelet count recovers to &ge;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     . If platelet count &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , discontinue dalteparin until platelet count recover to &gt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Obesity:",
"     </i>",
"     Use actual body weight to calculate dose; dose capping is not recommended (Nutescu, 2009). However, the manufacturer recommends a maximum dose of 18,000 units per day for the treatment of VTE in cancer patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      DVT (with or without PE) treatment in noncancer patients (unlabeled use in U.S.):",
"     </b>",
"     SubQ: 200 units/kg once daily (Feissinger, 1996; Jaff, 2011; Wells, 2005)",
"     <b>",
"      or",
"     </b>",
"     100 units/kg twice daily (Jaff, 2011). Use of once daily administration is suggested (Guyatt, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     SubQ: 200 units/kg once daily (maximum dose: 18,000 units/day)",
"     <b>",
"      or",
"     </b>",
"     alternatively, may adapt dose as follows (SubQ):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     46-56 kg: 10,000 units once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     57-68 kg: 12,500 units once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     69-82 kg: 15,000 units once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     &ge;83 kg: 18,000 units once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     If increased bleeding risk, may give 100 units/kg SubQ twice daily. Concomitant treatment with a vitamin-K antagonist is usually initiated immediately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Obesity:",
"     </i>",
"     Use actual body weight to calculate dose; dose capping is not recommended (Nutescu, 2009). One study demonstrated similar anti-Xa levels after 3 days of therapy in obese patients (&gt;40% above IBW; range: 82-190 kg) compared to those &le;20% above IBW or between 20% to 40% above IBW (Wilson, 2001).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Pregnant women:",
"     </i>",
"     200 units/kg/dose once daily or 100 units/kg/dose every 12 hours. Discontinue &ge;24 hours prior to the induction of labor or cesarean section. Dalteparin therapy may be substituted with heparin near term. Continue anticoagulation therapy for &ge;6 weeks postpartum (minimum duration of therapy: 3 months). LMWH or heparin therapy is preferred over warfarin during pregnancy (Bates, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Prevention of recurrent venous thromboembolism in pregnancy (unlabeled use):",
"     </b>",
"     SubQ: 5000 units once daily. Therapy should continue for 6 weeks postpartum in high-risk women (Bates, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F156484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F4804012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Half-life is increased in patients with chronic renal failure, use with caution, accumulation can be expected; specific dosage adjustments have not been recommended. Accumulation was not observed in critically ill patients with severe renal insufficiency (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute) receiving prophylactic doses (5000 units) for a median of 7 days (Douketis, 2008). In cancer patients, receiving treatment for venous thromboembolism, if Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute, manufacturer recommends monitoring anti-Xa levels to determine appropriate dose.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F7676342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F156459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fragmin&reg;: 25,000 anti-Xa units/mL (3.8 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fragmin&reg;: 10,000 anti-Xa units/mL (1 mL); 2500 anti-Xa units/0.2 mL (0.2 mL); 5000 anti-Xa units/0.2 mL (0.2 mL); 7500 anti-Xa units/0.3 mL (0.3 mL); 12,500 anti-Xa units/0.5 mL (0.5 mL); 15,000 anti-Xa units/0.6 mL (0.6 mL); 18,000 anti-Xa  units/0.72 mL (0.72 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F156445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F156462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     For deep SubQ injection; may be injected in a U-shape to the area surrounding the navel, the upper outer side of the thigh, or the upper outer quadrangle of the buttock. Use thumb and forefinger to lift a fold of skin when injecting dalteparin to the navel area or thigh. Insert needle at a 45- to 90-degree angle. The entire length of needle should be inserted. Do not expel air bubble from fixed-dose syringe prior to injection. Air bubble (and extra solution, if applicable) may be expelled from graduated syringes. In order to minimize bruising, do not rub injection site.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     To convert from I.V. unfractionated heparin (UFH) infusion to SubQ dalteparin (Nutescu, 2007): Calculate specific dose for dalteparin based on indication, discontinue UFH and begin dalteparin within 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     To convert from SubQ dalteparin to I.V. UFH infusion (Nutescu, 2007): Discontinue dalteparin; calculate specific dose for I.V. UFH infusion based on indication; omit heparin bolus/loading dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Converting from SubQ dalteparin dosed every 12 hours:",
"     </i>",
"     Start I.V. UFH infusion 10-11 hours after last dose of dalteparin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Converting from SubQ dalteparin dosed every 24 hours:",
"     </i>",
"     Start I.V. UFH infusion 22-23 hours after last dose of dalteparin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     I.V. (Canadian labeling; not an approved route in U.S. labeling): Administer as bolus I.V. injection or as continuous infusion. Recommended concentration for infusion: 20 units/mL.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F156460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of deep vein thrombosis (DVT) which may lead to pulmonary embolism, in patients requiring abdominal surgery who are at risk for thromboembolism complications (eg, patients &gt;40 years of age, obesity, patients with malignancy, history of DVT or pulmonary embolism, and surgical procedures requiring general anesthesia and lasting &gt;30 minutes); prevention of DVT in patients undergoing hip-replacement surgery; patients immobile during an acute illness; prevention of ischemic complications in patients with unstable angina or non-Q-wave myocardial infarction on concurrent aspirin therapy; in patients with cancer, extended treatment (6 months) of acute symptomatic venous thromboembolism (DVT and/or PE) to reduce the recurrence of venous thromboembolism",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional use (unlabeled use in U.S.): Treatment of acute DVT; prevention of venous thromboembolism (VTE) in patients at risk of VTE undergoing general surgery; anticoagulant in extracorporeal circuit during hemodialysis and hemofiltration",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F14943670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Active treatment of deep vein thrombosis (noncancer patients)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5174521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      National Patient Safety Goals:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Joint Commission (TJC) requires healthcare organizations that provide anticoagulant therapy to have a process in place to reduce the risk of anticoagulant-associated patient harm. Patients receiving anticoagulants should receive individualized care through a defined process that includes standardized ordering, dispensing, administration, monitoring, and education. This does not apply to routine short-term use of anticoagulants for prevention of venous thromboembolism when the expectation is that the patient&rsquo;s laboratory values will remain within or close to normal values (NPSG.03.05.01).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F156516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     As with all anticoagulants, bleeding is the major adverse effect of dalteparin. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Hematologic: Bleeding (3% to 14%), thrombocytopenia (including heparin-induced thrombocytopenia, &lt;1%; cancer clinical trials: ~11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Major bleeding (up to 6%), wound hematoma (up to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: AST &gt;3 times upper limit of normal (5% to 9%), ALT &gt;3 times upper limit of normal (4% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Pain at injection site (up to 12%), injection site hematoma (up to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reaction (fever, pruritus, rash, injections site reaction, bullous eruption), alopecia, anaphylactoid reaction, gastrointestinal bleeding, hemoptysis, operative site bleeding, skin necrosis, subdural hematoma, thrombosis (associated with heparin-induced thrombocytopenia). Spinal or epidural hematomas can occur following neuraxial anesthesia or spinal puncture, resulting in paralysis.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F156465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dalteparin (eg, pruritus, rash, anaphylactic reactions) or any component of the formulation; history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis; hypersensitivity to heparin or pork products; active major bleeding; patients with unstable angina, non-Q-wave MI, or prolonged venous thromboembolism prophylaxis undergoing epidural/neuraxial anesthesia",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Use of dalteparin in patients with current HIT or HIT with thrombosis is",
"     <b>",
"      not",
"     </b>",
"     recommended and considered contraindicated due to high cross-reactivity to heparin-platelet factor-4 antibody (Guyatt [ACCP], 2012; Warkentin, 1999).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Septic endocarditis, major blood clotting disorders; acute gastroduodenal ulcer; cerebral hemorrhage; severe uncontrolled hypertension; diabetic or hemorrhagic retinopathy; other diseases that increase risk of hemorrhage; injuries to and operations on the CNS, eyes, and ears",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F156449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding: Monitor patient closely for signs or symptoms of bleeding. Certain patients are at increased risk of bleeding. Risk factors include bacterial endocarditis; congenital or acquired bleeding disorders; active ulcerative or angiodysplastic GI diseases; severe uncontrolled hypertension; hemorrhagic stroke; or use shortly after brain, spinal, or ophthalmology surgery; in patients treated concomitantly with platelet inhibitors; recent GI bleeding; thrombocytopenia or platelet defects; severe liver disease; hypertensive or diabetic retinopathy; or in patients undergoing invasive procedures. Discontinue if bleeding occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: Monitor for hyperkalemia. Heparin can cause hyperkalemia by affecting aldosterone; similar reactions could occur with LMWHs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombocytopenia: Cases of dalteparin-induced thrombocytopenia and thrombosis (similar to heparin-induced thrombocytopenia [HIT]), some complicated by organ infarction, limb ischemia, or death, have been observed. In patients with a history of  HIT or HIT with thrombosis, dalteparin is contraindicated. Consider discontinuation of therapy in any patient developing significant thrombocytopenia (eg, &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ) and/or thrombosis related to initiation of dalteparin especially when associated with a positive",
"     <i>",
"      in vitro",
"     </i>",
"     test for antiplatelet antibodies. Use caution in patients with congenital or drug-induced thrombocytopenia or platelet defects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cancer: Cancer patients with thrombocytopenia may require dose adjustments for treatment of acute venous thromboembolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment; accumulation may occur with repeated dosing increasing the risk for bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obesity: There is no consensus for adjusting/correcting the weight-based dosage of LMWH for patients who are morbidly obese (BMI &ge;40 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ). Monitoring of anti-Xa levels 4 hours after the dose may be warranted. The American College of Chest Physicians Practice Guidelines suggest consulting with a pharmacist regarding dosing in bariatric surgery patients and other obese patients who may require higher doses of LMWH (Gould, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Multidose vials: Contain benzyl alcohol and should not be used in pregnant women. In neonates, large amounts of benzyl alcohol (&gt;100 mg/kg/day) have been associated with fatal toxicity (gasping syndrome).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conversion to other products: Not to be used interchangeably (unit for unit) with heparin or any other low molecular weight heparins.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuraxial anesthesia:",
"     <b>",
"      [U.S. Boxed Warning]: Spinal or epidural hematomas, including subsequent paralysis, may occur with recent or anticipated neuraxial anesthesia (epidural or spinal anesthesia) or spinal puncture in patients anticoagulated with LMWH or heparinoids.",
"     </b>",
"     Consider risk versus benefit prior to spinal procedures; risk is increased by the use of concomitant agents which may alter hemostasis, the use of indwelling epidural catheters for analgesia, a history of spinal deformity or spinal surgery, as well as a history of traumatic or repeated epidural or spinal punctures. Use of dalteparin is contraindicated in patients who will be undergoing epidural/neuraxial anesthesia. Patient should be observed closely for bleeding and signs and symptoms of neurological impairment if therapy is administered during or immediately following diagnostic lumbar puncture, epidural anesthesia, or spinal anesthesia.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F156453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     5-ASA Derivatives: May enhance the adverse/toxic effect of Heparin (Low Molecular Weight). Specifically, the risk for bleeding/bruising may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: May enhance the anticoagulant effect of other Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Heparin (Low Molecular Weight) may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: Potential benefits of therapeutic doses of LMW heparins should be weighed against an increased risk of bleeding in patients who receive drotrecogin alfa.  In patients receiving prophylactic LMW heparin doses consider continuing this during drotrecogin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Palifermin: Heparin (Low Molecular Weight) may increase the serum concentration of Palifermin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the anticoagulant effect of Heparin (Low Molecular Weight).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Anticoagulants may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the anticoagulant effect of Anticoagulants. Vitamin E may also increase the overall risk for bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F156476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Alfalfa, anise, bilberry, bladderwrack, bromelain, cat's claw, celery, chamomile, coleus, cordyceps, dong quai, evening primrose oil, fenugreek, feverfew, garlic, ginger, ginkgo biloba, ginseng (American), ginseng (panax), ginseng (Siberian), grapeseed, green tea, guggul, horse chestnut seed, horseradish, licorice, prickly ash, red clover, reishi, SAMe (s-adenosylmethionine), sweet clover, turmeric, white willow (all have additional antiplatelet/anticoagulant activity)",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F156455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F156468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were not observed in animal reproduction studies. Low molecular weight heparin (LMWH) does not cross the placenta; increased risks of fetal bleeding or teratogenic effects have not been reported.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     LMWH is recommended over unfractionated heparin for the treatment of acute venous thromboembolism (VTE) in pregnant women. LMWH is also recommended over unfractionated heparin for VTE prophylaxis in pregnant women with certain risk factors. LMWH should be discontinued at least 24 hours prior to induction of labor or a planned cesarean delivery. For women undergoing cesarean section and who have additional risk factors for developing VTE, the prophylactic use of LMWH may be considered. For women who require long-term anticoagulation with warfarin and who are considering pregnancy, LMWH substitution should be done prior to conception when possible. When choosing therapy, fetal outcomes (ie, pregnancy loss, malformations), maternal outcomes (ie, VTE, hemorrhage), burden of therapy, and maternal preference should be considered (Guyatt, 2012). Multiple-dose vials contain benzyl alcohol (avoid in pregnant women due to association with gasping syndrome in premature infants); use of preservative-free formulation is recommended.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F156487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F4801185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In lactating women receiving prophylactic doses of dalteparin, small amounts of anti-xa activity was noted in breast milk. The milk/plasma ratio was &lt;0.025 to 0.224. Oral absorption of low molecular weight heparin is extremely low, and is therefore unlikely to cause adverse events in a nursing infant. Use of LMWH may be continued in breast-feeding women (Guyatt, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Fragmin Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2500 units/0.2 mL (0.2 mL): $26.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5000 units/0.2 mL (0.2 mL): $42.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7500 unit/0.3 mL (0.3 mL): $63.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10000 units/mL (1 mL): $85.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12500 units/0.5 mL (0.5 mL): $106.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15000 unit/0.6 mL (0.6 mL): $127.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     18000 units (0.72 mL): $153.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25000 units/mL (3.8 mL): $731.30",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F156457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic CBC including platelet count; stool occult blood tests; monitoring of PT and PTT is not necessary. Once patient has received 3-4 doses, anti-Xa levels, drawn 4-6 hours after dalteparin administration, may be used to monitor effect in patients with severe renal dysfunction or if abnormal coagulation parameters or bleeding should occur. For patients &gt;190 kg, if anti-Xa monitoring is available, adjusting dose based on anti-Xa levels is recommended; if anti-Xa monitoring is unavailable, reduce dose if bleeding occurs (Nutescu, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F4802962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Recurrent VTE prophylaxis in pregnant women: Peak anti-Xa concentrations: 0.2-0.6 units/mL (Bates,  2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treatment of venous thromboembolism: Peak anti-Xa concentration target (measured 4 hours after administration):",
"     <i>",
"      Once-daily dosing:",
"     </i>",
"     1.05 anti-Xa units/mL (Garcia, 2012); per the manufacturer, target anti-Xa range is 0.5-1.5 units/mL (measured 4-6 hours after administration and after patient received 3-4 doses)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F156469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Conpac (TW);",
"     </li>",
"     <li>",
"      Eurodal (PH);",
"     </li>",
"     <li>",
"      Fragmin (AE, AT, AU, BE, BG, BH, BR, CH, CL, CN, CO, CY, CZ, DK, EC, EG, ES, FI, GB, GR, HK, HN, IE, IL, IN, IQ, IR, IT, JO, KP, KW, LB, LY, NL, NO, OM, PE, PK, PL, PT, QA, RU, SA, SE, SG, SY, TR, TW, YE, ZA);",
"     </li>",
"     <li>",
"      Fragmin P Forte (DE);",
"     </li>",
"     <li>",
"      Fragmine (FR);",
"     </li>",
"     <li>",
"      Ligofragmin (AR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F156448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Low molecular weight heparin analog with a molecular weight of 4000-6000 daltons; the commercial product contains 3% to 15% heparin with a molecular weight &lt;3000 daltons, 65% to 78% with a molecular weight of 3000-8000 daltons and 14% to 26% with a molecular weight &gt;8000 daltons; while dalteparin has been shown to inhibit both factor Xa and factor IIa (thrombin), the antithrombotic effect of dalteparin is characterized by a higher ratio of antifactor Xa to antifactor IIa activity (ratio = 4)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F156464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Anti-Xa activity: Within 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: &gt;12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 40-60 mL/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Low affinity for plasma proteins (Howard, 1997)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: SubQ: 81% to 93%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination (route dependent): Anti-Xa activity: 2-5 hours; prolonged in chronic renal insufficiency: 3.7-7.7 hours (following a single 5000 unit dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Anti-Xa activity: ~4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily renal (Howard, 1997)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bates SM, Greer IA, Middeldorp S, et al. &ldquo;VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):e691-736.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/56/32648/abstract-text/22315276/pubmed\" id=\"22315276\" target=\"_blank\">",
"        22315276",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Braunwald E, Antman EM, Beasley JW, et al, &ldquo;ACC/AHA 2002 Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction - Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina),&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2002, 40(7):1366-74. Available at: file://www.acc.org/clinical/guidelines/unstable/incorporated/index.htm. Accessed May 20, 2003.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/56/32648/abstract-text/12383588/pubmed\" id=\"12383588\" target=\"_blank\">",
"        12383588",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/56/32648/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Douketis J, Cook D, Meade M, et al, \"Prophylaxis Against Deep Vein Thrombosis in Critically Ill Patients With Severe Renal Insufficiency With the Low-Molecular-Weight Heparin Dalteparin: An Assessment of Safety and Pharmacodynamics: the DIRECT Study,\"",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2008, 168(16):1805-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/56/32648/abstract-text/18779469/pubmed\" id=\"18779469\" target=\"_blank\">",
"        18779469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fiessinger JN, Lopez-Fernandez M, Gatterer E, et al, &ldquo;Once-Daily Subcutaneous Dalteparin, a Low Molecular Weight Heparin, for the Initial Treatment of Acute Deep Vein Thrombosis,&rdquo;",
"      <i>",
"       Thromb Haemost",
"      </i>",
"      , 1996, 76(2):195-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/56/32648/abstract-text/8865530/pubmed\" id=\"8865530\" target=\"_blank\">",
"        8865530",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frostfeldt G, Ahlberg G, Gustafsson G, et al, &ldquo;Low Molecular Weight Heparin (Dalteparin) as Adjunctive Treatment of Thrombolysis in Acute Myocardial Infarction - A Pilot Study: Biochemical Markers in Acute Coronary Syndromes (BIOMACS II),",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1999, 33(3):627-33.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garcia DA, Baglin TP, Weitz JI, et al, &ldquo;Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):24-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/56/32648/abstract-text/22315264/pubmed\" id=\"22315264\" target=\"_blank\">",
"        22315264",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gould MK, Garcia DA, Wren SM, et al, &ldquo;Prevention of VTE in Nonorthopedic Surgical Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):e227-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/56/32648/abstract-text/22315263/pubmed\" id=\"22315263\" target=\"_blank\">",
"        22315263",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):7-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/56/32648/abstract-text/22315257/pubmed\" id=\"22315257\" target=\"_blank\">",
"        22315257",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Howard PA, &ldquo;Dalteparin: A Low-Molecular-Weight-Heparin,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1997, 31(2):192-203.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/56/32648/abstract-text/9034422/pubmed\" id=\"9034422\" target=\"_blank\">",
"        9034422",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Invasive Compared With Noninvasive Treatment in Unstable Coronary-Artery Disease: FRISC II Prospective Randomised Multicentre Study. Fragmin&reg; and Fast Revascularisation During Instability in Coronary Artery Disease Investigators,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1999, 354(9180):708-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/56/32648/abstract-text/10475181/pubmed\" id=\"10475181\" target=\"_blank\">",
"        10475181",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jaff MR, McMurtry MS, Archer SL, et al, &ldquo;Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension: A Scientific Statement from the American Heart Association,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(16):1788-830.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/56/32648/abstract-text/21422387/pubmed\" id=\"21422387\" target=\"_blank\">",
"        21422387",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jauch EC, Saver JL, Adams HP Jr, et al, &ldquo;Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association,&rdquo;",
"      <i>",
"       Stroke",
"      </i>",
"      , 2013, 44(3):870-947.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/56/32648/abstract-text/23370205/pubmed\" id=\"23370205\" target=\"_blank\">",
"        23370205",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Klein W, Buchwald A, Hillis SE, et al, &ldquo;Comparison of Low Molecular-Weight Heparin With Unfractionated Heparin Acutely and With Placebo for 6 Weeks in the Management of Unstable Coronary Artery Disease. Fragmin&reg; in Unstable Coronary Artery Disease Study,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1997, 96(1):61-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/56/32648/abstract-text/9236418/pubmed\" id=\"9236418\" target=\"_blank\">",
"        9236418",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kontny F, Dale, J Abildgaard U, et al, &ldquo;Randomized Trial of Low Molecular Weight Heparin (Dalteparin) in Prevention of Left Ventricular Thrombus Formation and Arterial Embolism After Acute Anterior Myocardial Infarction: The Fragmin&reg; in Acute Myocardial Infarction (FRAMI) Study,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1997, 30(4):962-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/56/32648/abstract-text/9316525/pubmed\" id=\"9316525\" target=\"_blank\">",
"        9316525",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee AY, Levine MN, Baker RI, et al, &ldquo;Low-Molecular-Weight Heparin Versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 349(2):146-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/56/32648/abstract-text/12853587/pubmed\" id=\"12853587\" target=\"_blank\">",
"        12853587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee AY, Rickels FR, Julian JA, et al, &ldquo;Randomized Comparison of Low Molecular Weight Heparin and Coumarin Derivatives on the Survival of Patients With Cancer and Venous Thromboembolism,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(10):2123-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/56/32648/abstract-text/15699480/pubmed\" id=\"15699480\" target=\"_blank\">",
"        15699480",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Long-Term Low-Molecular-Mass Heparin in Unstable Coronary-Artery Disease: FRISC II Prospective Randomised Multicentre Study. Fragmin&reg; and Fast Revascularization During Instability in Coronary Artery Disease Investigators,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1999, 354(9180):701-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Low-Molecular-Weight Heparin During Instability in Coronary Artery Disease, Fragmin&reg; During Instability in Coronary Artery Disease (FRISC) Study Group,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1996, 347(9001):561-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/56/32648/abstract-text/8596317/pubmed\" id=\"8596317\" target=\"_blank\">",
"        8596317",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mechanick JI, Kushner RF, Sugerman HJ, et al, &ldquo;American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic &amp; Bariatric Surgery Medical Guidelines for Clinical Practice for the Perioperative Nutritional, Metabolic, and Nonsurgical Support of the Bariatric Surgery Patient,&rdquo;",
"      <i>",
"       Obesity",
"      </i>",
"      , 2009, 17(Suppl 1):1-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/56/32648/abstract-text/19319140/pubmed\" id=\"19319140\" target=\"_blank\">",
"        19319140",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nagge J, Crowther M, and Hirsh J, &ldquo;Is Impaired Renal Function a Contraindication to the Use of Low-Molecular Weight Heparin?&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2002, 162(22):2605-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/56/32648/abstract-text/12456233/pubmed\" id=\"12456233\" target=\"_blank\">",
"        12456233",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nutescu EA and Dager W, &ldquo;Heparin, Low Molecular Weight Heparin, and Fondaparinux,&rdquo;",
"      <i>",
"       Managing Anticoagulation Patients in the Hospital",
"      </i>",
"      , Gulseth M ed, American Society of Health-System Pharmacists&reg;, Bethesda, MD: 2007, 181.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nutescu EA, Spinler SA, Wittkowsky A, et al, &ldquo;Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical Settings,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2009, 43(6):1064-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/56/32648/abstract-text/19458109/pubmed\" id=\"19458109\" target=\"_blank\">",
"        19458109",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group, &ldquo;Dalteparin versus Unfractionated Heparin in Critically Ill Patients,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 364(14):1305-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/56/32648/abstract-text/21417952/pubmed\" id=\"21417952\" target=\"_blank\">",
"        21417952",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stobe J, Siegemund A, Achenbach H, et al, &ldquo;Evaluation of the Pharmacokinetics of Dalteparin in Patients With Renal Insufficiency,&rdquo;",
"      <i>",
"       Int J Clin Pharmacol Ther",
"      </i>",
"      , 2006, 44(10):455-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/56/32648/abstract-text/17063975/pubmed\" id=\"17063975\" target=\"_blank\">",
"        17063975",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wallentin L, &ldquo;ASSENT 3 PLUS,&rdquo; [Paper presented at] American Heart Association 75th Scientific Sessions, November 17-20, 2002; Chicago, Ill.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Warkentin TE and Barkin RL, &ldquo;Newer Strategies for the Treatment of Heparin-Induced Thrombocytopenia,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1999, 19(2):181-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/56/32648/abstract-text/10030768/pubmed\" id=\"10030768\" target=\"_blank\">",
"        10030768",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wells PS, Anderson DR, Rodger MA, et al, &ldquo;Randomized Trial Comparing 2 Low-Molecular-Weight Heparins for the Outpatient Treatment of Deep Vein Thrombosis and Pulmonary Embolism,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2005, 165(7):733-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/56/32648/abstract-text/15824291/pubmed\" id=\"15824291\" target=\"_blank\">",
"        15824291",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilson SJ, Wilbur K, Burton E, et al, &ldquo;Effect of Patient Weight on the Anticoagulant Response to Adjusted Therapeutic Dosage of Low-Molecular-Weight Heparin for the Treatment of Venous Thromboembolism,&rdquo;",
"      <i>",
"       Haemostasis",
"      </i>",
"      , 2001, 31(1):42-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wong GC, Giugliano RP, and Antman EM, &ldquo;Use of Low-Molecular-Weight Heparins in the Management of Acute Coronary Artery Syndromes and Percutaneous Coronary Intervention,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(3):331-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/56/32648/abstract-text/12525234/pubmed\" id=\"12525234\" target=\"_blank\">",
"        12525234",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zed PJ, Tisdale JE, and Borzak S, &ldquo;Low-Molecular-Weight Heparins in the Management of Acute Coronary Syndromes,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1999, 159(16):1849-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/56/32648/abstract-text/10493315/pubmed\" id=\"10493315\" target=\"_blank\">",
"        10493315",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9319 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-5A1610FE52-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_56_32648=[""].join("\n");
var outline_f31_56_32648=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708690\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156480\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156481\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156518\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156483\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156484\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4804012\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7676342\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156459\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156445\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156462\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156460\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14943670\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174521\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156516\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156465\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156449\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299121\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156453\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156476\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156455\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156468\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156487\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4801185\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422208\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156457\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4802962\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156469\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156448\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156464\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9319\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9319|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/17/2325?source=related_link\">",
"      Dalteparin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_56_32649="Induction immunosuppressive therapy in renal transplantation in adults";
var content_f31_56_32649=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Induction immunosuppressive therapy in renal transplantation in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/56/32649/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/56/32649/contributors\">",
"     John Vella, MD, FACP, FRCP, FASN",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/56/32649/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/56/32649/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/56/32649/contributors\">",
"     Barbara Murphy, MB, BAO, BCh, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/56/32649/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/56/32649/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/56/32649/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, induction immunosuppressive strategies utilized by kidney transplant centers fall into one of two categories (",
"    <a class=\"graphic graphic_table graphicRef73471 \" href=\"mobipreview.htm?17/50/18219\">",
"     table 1",
"    </a>",
"    ). One strategy relies upon high doses of conventional immunosuppressive agents, while the other utilizes antibodies directed against T-cell antigens in combination with lower doses of conventional agents.",
"   </p>",
"   <p>",
"    The optimal prophylactic induction immunosuppressive therapy to prevent kidney transplant rejection remains controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. What follows in this topic review is a summary of the current data and our approach to induction therapy in adults. Maintenance immunosuppressive therapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43706?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF OUR APPROACH TO INDUCTION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Practically all kidney allograft recipients require immunosuppressive therapy to prevent rejection and loss of the allograft. The optimal regimen, including induction therapy, is not clear. A large number of controlled randomized trials and meta-analyses indicate that induction therapy consisting of biologic antibodies plus conventional immunosuppressive agent therapy is superior to conventional agent therapy alone in reducing kidney allograft rejection and allograft failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients undergoing kidney transplantation, we therefore recommend induction therapy consisting of antibody therapy plus conventional immunosuppressive therapy. One exception is Caucasian recipients of two haplotype-identical living related allografts. Such patients do not generally require induction therapy with antibodies given their markedly decreased immunologic risk of acute rejection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Immunosuppressive antibody therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Currently available antibodies include the following specific anti-lymphocyte or interleukin-2 receptor antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anti-lymphocyte antibodies &mdash; Anti-lymphocyte antibodies include both polyclonal and monoclonal antibodies. Thymoglobulin (Genzyme, Cambridge, MA) is a polyclonal immunosuppressive agent that is generated in rabbits. Although there is no generic formulation, it is commonly referred to as rATG. This may produce some confusion as there are other rabbit anti-thymocyte globulins (ATGs) such as one produced by Fresenius. The immunogen for rATG-thymoglobulin is human thymocytes, while for rATG-Fresenius the immunogen is a Jurkat T-cell leukemia line. The preparations also differ in potency and efficacy. Throughout the remainder of this topic review, rATG-thymoglobulin will refer to Thymoglobulin. Another polyclonal antibody, ATGAM, is a purified gamma globulin solution. It is obtained by immunization of horses with human thymocytes.",
"      <br/>",
"      <br/>",
"      All of the previously described agents contain antibodies to a wide variety of human T-cell surface antigens, including the major histocompatibility complex (MHC) antigens. Monoclonal anti-lymphocyte antibodies include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      and OKT3. Alemtuzumab (Campath-1H) is a humanized anti-CD52 panlymphocytic (both B and T cells) monoclonal antibody, while OKT3 is a mouse antibody directed against the CD3 antigen that is closely associated with the T-cell receptor.",
"     </li>",
"     <li>",
"      Interleukin-2 receptor antagonists &mdash; Full T-cell activation leads to the calcineurin-mediated stimulation of the transcription, translation, and secretion of interleukin-2 (IL-2), an essential autocrine growth factor that induces T-cell proliferation. Thus, an attractive therapeutic option is the abrogation of IL-2 activity via the administration of anti-IL-2 receptor antibodies. The only IL-2 receptor antibody that is currently available is",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22374?source=see_link\">",
"       basiliximab",
"      </a>",
"      . The manufacturer voluntarily withdrew the marketing authorization for another interleukin-2 receptor antibody, daclizumab (Zenapax&trade;), in October, 2008 in all countries where it is licensed. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'IL-2 receptor antibodies'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of trials have been and are being conducted to look at the effects of the different prophylactic antibody induction therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. Evaluation of these trials or of any induction protocol requires consideration of the following factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Incidence and severity of delayed allograft function or primary nonfunction, including the requirement for and duration of dialysis following transplantation",
"     </li>",
"     <li>",
"      Incidence of acute rejection",
"     </li>",
"     <li>",
"      Incidence, type, and severity of associated infections",
"     </li>",
"     <li>",
"      Long-term allograft survival and function",
"     </li>",
"     <li>",
"      Mortality and morbidity, including length of hospitalization",
"     </li>",
"     <li>",
"      Cost",
"     </li>",
"     <li>",
"      Incidence and type of malignancy during long-term follow-up",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An important element to some current approaches to induction protocols involves the attempt to identify patients at high risk of acute rejection. With this view, more aggressive immunosuppression is justified in patients at significantly increased risk of rejection. In the 2009 KDIGO clinical practice guidelines, for example, risk factors for acute rejection include one or more of the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased number of HLA mismatches",
"     </li>",
"     <li>",
"      Younger recipient and older donor age",
"     </li>",
"     <li>",
"      African-American ethnicity (in the United States)",
"     </li>",
"     <li>",
"      Panel reactive antibody (PRA) greater than zero percent",
"     </li>",
"     <li>",
"      Presence of a donor-specific antibody",
"     </li>",
"     <li>",
"      Blood group incompatibility",
"     </li>",
"     <li>",
"      Delayed onset of graft function",
"     </li>",
"     <li>",
"      Cold ischemia time greater than 24 hours",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In such patients, the 2009 guidelines suggest the use of lymphocyte depleting agents, which are potent immunosuppressive agents, rather than interleukin-2 receptor antibodies. By comparison, among patients not at high immunologic risk, the guidelines recommend the use of interleukin-2 receptor antibodies due in part to meta-analysis showing a decreased risk of rejection with these agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Our approach differs. There is substantial evidence that rATG-thymoglobulin is superior to interleukin-2 receptor antibodies and placebo among patients at both high as well as low immunologic risk who are receiving concurrent immunosuppressive regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. Given these results, we therefore currently administer rATG-thymoglobulin, a lymphocyte depleting agent, rather than an interleukin-2 receptor antagonist to most patients undergoing kidney transplantation. Exceptions to this approach include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients unable to tolerate rATG-thymoglobulin, such as those who are hypotensive, leukopenic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      thrombocytopenic at the time of presentation. We administer the interleukin-2 receptor antagonist,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22374?source=see_link\">",
"       basiliximab",
"      </a>",
"      , to such patients.",
"     </li>",
"     <li>",
"      Caucasian recipients of two haplotype identical living related kidneys. We do not administer antibody therapy as part of the induction regimen in this group.",
"     </li>",
"     <li>",
"      Recipients of a kidney transplant who have another functioning solid organ transplant such as a liver, lung, or heart and are currently being administered immunosuppressive agents.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nonimmunosuppressive components",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial therapeutic regimen consists of more than the administration of immunosuppressive agents. As an example, both the donor and recipient should be tested for CMV status; most centers are currently using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    as primary prophylaxis therapy in patients at risk for CMV infection. We also administer prophylactic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    to prevent Pneumocystis carinii pneumonia, sepsis, and urinary tract infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29738?source=see_link\">",
"     \"Cytomegalovirus infection in renal transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/9/40084?source=see_link&amp;anchor=H5#H5\">",
"     \"Differential diagnosis of infection following renal transplantation\", section on 'Antimicrobial prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     POLYCLONAL ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the redundancy of the immune system, polyclonal antibodies, which have a broad specificity, should be theoretically more effective in induction therapy than monoclonal antilymphocyte agents (such as OKT3, which targets CD3,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    , which targets CD52, or monoclonal anti-interleukin 2 receptor antagonists, which target CD25 [see below]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As previously mentioned, the two principal polyclonal antibodies available in the United States are rATG-thymoglobulin and ATGAM. We consider rATG-thymoglobulin to be superior to ATGAM, interleukin-2 receptor antibodies, and placebo among kidney transplant recipients at both high as well as low immunologic risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. As a result, we currently administer rATG-thymoglobulin, a lymphocyte depleting agent, to most patients undergoing kidney transplantation as part of induction immunosuppressive therapy.",
"   </p>",
"   <p>",
"    Although the administration of rATG-thymoglobulin offers clinical advantages even in low-risk groups, the KDIGO guidelines currently recommend use of rATG-thymoglobulin principally for groups at high-risk for allograft rejection. A high-risk patient as defined by the KDIGO guidelines is described in the previous section. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Immunosuppressive antibody therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     rATG-thymoglobulin versus ATGAM",
"    </span>",
"    &nbsp;&mdash;&nbsp;rATG-thymoglobulin is more effective than ATGAM in lowering the acute rejection rate and improved allograft survival. This was shown in a trial in which 72 transplant recipients were randomly assigned in a double-blind 2:1 fashion to receive rATG-thymoglobulin (48 patients) at 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously or ATGAM (24 patients) at 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously, intraoperatively, then daily for at least six days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/16\">",
"     16",
"    </a>",
"    ]. The delayed graft function rate was only 1 percent for both groups. At one year, the group administered rATG-thymoglobulin had a significantly lower acute rejection rate (4 versus 25 percent, respectively) and higher allograft survival (98 versus 83 percent).",
"   </p>",
"   <p>",
"    The lower rejection rate was thought to be due in part to a more sustained lymphopenia with rATG-thymoglobulin, while the exceptionally low delayed graft function rate seen in both groups may have been due to the intraoperative use of the ATGs; these antibodies have the ability to block a number of adhesion molecules, cytokines, chemokines, and their receptors, which may contribute to ischemia reperfusion injury and delayed graft function.",
"   </p>",
"   <p>",
"    Additional effects with further long-term follow-up were observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At two years, CD4+ counts were lower with the rATG-thymoglobulin group (227 versus 466",
"      <span class=\"nowrap\">",
"       cells/mm3",
"      </span>",
"      for ATGAM) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/17\">",
"       17",
"      </a>",
"      ]. CD8+ counts were similar for both groups.",
"     </li>",
"     <li>",
"      At five years, allograft survival was significantly better in the rATG-thymoglobulin arm (77 versus 57 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/17\">",
"       17",
"      </a>",
"      ]. Two cases of post-transplant lymphoproliferative disorder developed with ATGAM, while none were observed with rATG-thymoglobulin. The mean five-year serum creatinine concentration was similar in both groups.",
"     </li>",
"     <li>",
"      At 10 years, rATG-thymoglobulin was associated with decreased incidence of the composite of acute rejection, graft loss, and death (29 versus 48 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/18\">",
"       18",
"      </a>",
"      ]. The incidence of cancer was also lower in the rATG-thymoglobulin arm (8 versus 21 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both rATG-thymoglobulin and ATGAM reverse acute rejection, thereby possibly reducing the risks of developing chronic allograft nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. rATG-thymoglobulin appears to be superior to ATGAM for the reversal of acute rejection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/16,22\">",
"     16,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/52/4938?source=see_link\">",
"     \"Acute renal allograft rejection: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34778?source=see_link\">",
"     \"Chronic renal allograft nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    rATG-thymoglobulin administration also appears to be safe and effective in those undergoing living donor kidney transplantation, a low risk group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/12,23\">",
"     12,23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      This was shown in a single center study in which, compared to a national control group, rATG-thymoglobulin use provided superior five-year patient (96 versus 90 percent) and allograft survival (82 versus 79 percent), and one-year acute rejection rate (2 versus 21 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective study from another center found that rATG-thymoglobulin compared with no induction was associated with a significantly decreased acute rejection rate (2 versus 48 percent) without an increase in posttransplant complications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     rATG-thymoglobulin compared with IL-2 receptor antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described in detail below, rATG-thymoglobulin is more effective than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22374?source=see_link\">",
"     basiliximab",
"    </a>",
"    in preventing rejection in patients at both high and low immunologic risk of acute rejection. Among those at high risk, it has also clearly been shown to be more effective than daclizumab. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Efficacy of basiliximab compared with rATG-thymoglobulin'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H12\">",
"     'Daclizumab versus rATG-thymoglobulin'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Dosing strategies for rATG-thymoglobulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of varying dosing strategies for rATG-thymoglobulin as induction therapy have been evaluated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The efficacy and safety of a three-day induction regimen among 40 consecutive patients was compared to that of the seven-day course among a historic group of 48 patients evaluated by the investigators [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/24\">",
"       24",
"      </a>",
"      ]. With the three-day course, rATG-thymoglobulin was administered at 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intraoperatively followed by 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      on postoperative days one and two, while the seven-day course consisted of rATG-thymoglobulin at 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously intraoperatively, then daily for six days. At one year, there were no differences in acute rejection episodes (5 versus 4.2 percent for three- and seven-day regimen, respectively), graft survival (95 versus 98 percent) and patient survival (95 versus 98 percent), but the duration of initial hospital stay was significantly shorter in the three-day group (6.1 versus 8 days). A longer and more profound duration of lymphocyte depletion was also observed among those administered three days of rATG-thymoglobulin.",
"     </li>",
"     <li>",
"      Benefits with the intraoperative administration of rATG-thymoglobulin were observed in a prospective study in which 58 deceased donor transplant recipients were randomly assigned to receive either intraoperative or postoperative rATG-thymoglobulin therapy, with both groups receiving the same cumulative doses of the agent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/26\">",
"       26",
"      </a>",
"      ]. Intraoperative administration resulted in a significantly lower incidence of delayed graft function (15 and 36 percent) and a decreased posttransplant length of hospital stay.",
"     </li>",
"     <li>",
"      The efficacy of low dose rATG-thymoglobulin (0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22374?source=see_link\">",
"       basiliximab",
"      </a>",
"      versus standard dose rATG-thymoglobulin as induction therapy was evaluated in a randomized open label study of 33 consecutive high-risk patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/27\">",
"       27",
"      </a>",
"      ]. Both groups had similar patient and allograft survival, but adverse effects were significantly increased with the standard dose regimen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    rATG-thymoglobulin induction has been dosed from 1 to 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose, and the duration may range from 1 to 10 days, although a more typical regimen is 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    for three to five days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/7,16,24,26,28-32\">",
"     7,16,24,26,28-32",
"    </a>",
"    ]. In animal models, higher initial doses of shorter duration approximating a human-equivalent dose of 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    were associated with more peripheral and central lymphocyte depletion and better allograft survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on these models, the optimal induction dose is felt to total 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/24,30,32\">",
"     24,30,32",
"    </a>",
"    ]. Total doses of 5.7",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    on average given as 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day have been shown to produce similar outcomes in high-risk recipients who received an average of 10.3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/31\">",
"     31",
"    </a>",
"    ]. Higher doses and prolonged duration of induction agents are thought to be associated with an increased risk of infection and the potential development of lymphoma, while low doses &lt;3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    may not effectively prevent acute rejection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     How we administer rATG-thymoglobulin in combination with maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (7",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    and intravenous rATG-thymoglobulin (1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    are administered intraoperatively. rATG-thymoglobulin is administered if, at presentation, the white blood cell count is greater than",
"    <span class=\"nowrap\">",
"     2000/microL",
"    </span>",
"    and the platelet count is greater than",
"    <span class=\"nowrap\">",
"     75,000/microL.",
"    </span>",
"    We administer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22374?source=see_link\">",
"     basiliximab",
"    </a>",
"    if rATG-thymoglobulin cannot be given. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'IL-2 receptor antibodies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This initial intraoperative dose of rATG-thymoglobulin is followed by 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of rATG-thymoglobulin per day for the next two days (eg, a total of three doses). The dose of rATG-thymoglobulin is skipped if the white blood cell count falls to less than",
"    <span class=\"nowrap\">",
"     2000/microL",
"    </span>",
"    or the platelet count decreases to less than",
"    <span class=\"nowrap\">",
"     75,000/microL.",
"    </span>",
"    A half dose of rATG-thymoglobulin is administered for a white blood cell count between 2000 and",
"    <span class=\"nowrap\">",
"     3000/microL,",
"    </span>",
"    or a platelet count between 75,000 to",
"    <span class=\"nowrap\">",
"     100,000/microL.",
"    </span>",
"   </p>",
"   <p>",
"    This rATG-thymoglobulin regimen is combined with maintenance immunosuppressive therapy, which begins preoperatively with administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil 1000 mg on call to the operating room. Although described in detail elsewhere, the following is one triple drug regimen that can be combined with rATG-thymoglobulin induction therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43706?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subsequent maintenance therapy begins on postoperative day one with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    (0.05",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    orally two times per day adjusted to achieve a 12-hour trough level of 7 to 10",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    for the first month and 5 to 7",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    thereafter),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (1000 mg orally two times per day, which is reduced to 500 mg two times per day after five days or its molar equivalent of mycophenolic acid [360 mg two times per day]), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    orally for the first week, which is tapered by five weeks to 5 mg per day).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    , initiated at 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    orally two times per day, may be substituted for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    . Doses of cyclosporine are subsequently adjusted to attain target whole-blood trough concentrations of 150 to 300",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (by immunoassay) for the first three months post-transplant and 75 to 150",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    after this period.",
"   </p>",
"   <p>",
"    As an alternative to measuring",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    trough levels, C2 or two hours post-administration peak levels can also be used. Doses of cyclosporine are adjusted to generally target C2 levels to be 800 to 1400",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    for the first three months post-transplant and then 400 to 600",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    after this period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     IL-2 RECEPTOR ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of IL-2 receptor antibody therapy was best reported in a meta-analysis involving 38 trials that enrolled nearly 5000 patients, which assessed the impact of therapy on allograft loss and rejection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/3\">",
"     3",
"    </a>",
"    ]. Data were derived from published trials and abstracts of completed and ongoing trials. From these 38 trials, 14 trials enrolling 2410 patients compared IL-2R antagonists with placebo for at least one outcome. Compared with placebo, IL-2 receptor antagonists reduced acute rejection rates at six months (RR 0.66, CI 0.59 to 0.74) and one year (RR 0.67, CI 0.60 to 0.75), but the incidence of graft loss was the same.",
"   </p>",
"   <p>",
"    Only nine trials with a total enrollment of 778 patients examined the efficacy of IL-2 receptor antagonists versus other antibody therapy. Among these studies, other antibody therapy was associated with lower rates of biopsy-proven acute rejection, combined endpoint of graft loss and death, all cause mortality, and delayed graft function. However, significantly fewer adverse effects were observed with IL-2R antagonists.",
"   </p>",
"   <p>",
"    The only IL-2 receptor antibody that is currently available is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22374?source=see_link\">",
"     basiliximab",
"    </a>",
"    . Roche pharmaceuticals voluntarily withdrew the marketing authorization for another interleukin-2 receptor antibody, daclizumab (Zenapax&trade;), in October 2008 in all countries where it is licensed. This was a commercial decision due to the availability of alternative treatments, and hence diminished market demands. Stocks of the product existing in pharmacies and hospitals should continue to be available to patients until the end of shelf-life expiry in 2010.",
"   </p>",
"   <p>",
"    At present, we consider rATG-thymoglobulin to be superior to IL-2 receptor antibody therapy for antibody induction therapy in patients at low or high immunologic risk. Among those in whom rATG-thymoglobulin cannot be administered, we provide",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22374?source=see_link\">",
"     basiliximab",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    As a result, we administer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22374?source=see_link\">",
"     basiliximab",
"    </a>",
"    if, at presentation, the white blood cell count is less than",
"    <span class=\"nowrap\">",
"     2000/microL",
"    </span>",
"    or the platelet count is less than",
"    <span class=\"nowrap\">",
"     75,000/microL.",
"    </span>",
"    We also administer this agent to recipients of a kidney transplant after a previous solid organ transplant (eg, lung, liver, heart). We give 20 mg of basiliximab intraoperatively and 20 mg on postoperative day four.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Efficacy of basiliximab compared with rATG-thymoglobulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients at increased risk for acute rejection, rATG-thymoglobulin is more effective than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22374?source=see_link\">",
"     basiliximab",
"    </a>",
"    in preventing rejection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/10-13,34-37\">",
"     10-13,34-37",
"    </a>",
"    ]. Among such patients, the efficacy of basiliximab versus rATG-thymoglobulin in high risk patients was best assessed in a multicenter international randomized prospective study of 278 first deceased donor renal transplant recipients that compared the safety and efficacy of a five-day course of rATG-thymoglobulin (141) or two doses of basiliximab (137) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/10\">",
"     10",
"    </a>",
"    ]. Recipients and donors were chosen based upon characteristics that would predict a higher than normal risk for rejection or delayed graft function. Patients in both arms were also administered",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    for maintenance immunosuppression, and also received antiviral prophylaxis with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    per protocol.",
"   </p>",
"   <p>",
"    The primary endpoint was a composite of acute rejection, delayed allograft function, allograft loss, and death. At one year, the following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no difference between rATG-thymoglobulin and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22374?source=see_link\">",
"       basiliximab",
"      </a>",
"      in the incidence of the composite endpoint, allograft loss, delayed allograft function, and death.",
"     </li>",
"     <li>",
"      rATG-thymoglobulin was associated with a significantly lower acute rejection rate (16 versus 26 percent), and incidence of acute rejection that required antibody treatment (1.4 versus 8 percent).",
"     </li>",
"     <li>",
"      Although overall adverse event and serious adverse event rates were similar, rATG-thymoglobulin was associated with a higher incidence of infection (86 versus 75 percent) but lower incidence of cytomegalovirus disease (8 versus 18 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, although the primary endpoint at one year was similar in both arms, a significantly lower incidence of acute rejection was noted with rATG-thymoglobulin.",
"   </p>",
"   <p>",
"    At five-year follow-up, the incidence of acute rejection and need for antibody treatment of acute rejection remained lower among those treated with rATG-thymoglobulin compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22374?source=see_link\">",
"     basiliximab",
"    </a>",
"    (16 versus 30 percent and 3 versus 12 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/34\">",
"     34",
"    </a>",
"    ]. Patients treated with rATG-thymoglobulin also had a significantly lower composite endpoint of acute rejection, graft loss, and death at five years (39 versus 52 percent) and incidence of treated cytomegalovirus infection (7 versus 17 percent); however, the incidence of malignancy did not differ. Thus, the relative benefits of rATG-thymoglobulin were sustained over a five-year period after surgery.",
"   </p>",
"   <p>",
"    A retrospective study that compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22374?source=see_link\">",
"     basiliximab",
"    </a>",
"    with rATG-thymoglobulin in high-risk (for delayed function) patients also found that the incidence of acute rejection was significantly higher with basiliximab (26 versus 3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/35\">",
"     35",
"    </a>",
"    ]. Renal function, when measured at 3, 6, and 12 months, was also significantly lower among the group receiving basiliximab. However, a retrospective study that compared basiliximab with rATG-thymoglobulin in African-Americans, another high-risk group, found no difference with respect allograft outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although conflicting, there is some evidence that, compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22374?source=see_link\">",
"     basiliximab",
"    </a>",
"    , rATG-thymoglobulin may also be more beneficial in patients who receive a normotensive, standard criteria deceased donor kidney, a low-risk group. A subset analysis of a randomized controlled study of rATG-thymoglobulin compared to basiliximab in high-risk patients showed that recipients of a normotensive, standard criteria donor-kidney treated with rATG-thymoglobulin had less acute rejection, death, and a composite endpoint defined by death, graft loss, or acute rejection than their counterparts treated with basiliximab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/11\">",
"     11",
"    </a>",
"    ]. By comparison, another study, which was underpowered, found that basiliximab and rATG-thymoglobulin were similarly effective in low risk renal transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/36\">",
"     36",
"    </a>",
"    ]. In a one-year study of 105 such patients, both basiliximab and rATG-thymoglobulin resulted in similar allograft and patient survival rates as well as acute rejection rates; however, basiliximab was associated with a decreased incidence of adverse effects, including cytomegalovirus infection and leukopenia.",
"   </p>",
"   <p>",
"    Episodes of severe acute hypersensitivity have been described among patients either initially exposed to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22374?source=see_link\">",
"     basiliximab",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    following re-exposure after several months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Daclizumab versus rATG-thymoglobulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The greater efficacy of rATG-thymoglobulin over the IL-2R antagonists appears to be a class effect. Daclizumab was also found to be less effective than rATG-thymoglobulin in preventing acute rejection and steroid-resistant acute rejection among kidney transplant recipients at increased immunologic risk. A randomized study of 227 high risk patients found a lower incidence of acute rejection at one year among those who received rATG-thymoglobulin compared to patients administered daclizumab (15 versus 27 percent) as well as a lower incidence of steroid-resistant rejection (3 versus 15 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/40\">",
"     40",
"    </a>",
"    ]. Although one-year allograft and patient survival was the same with both agents, allograft survival was significantly higher in those without rejection (87 versus 75 percent). This study confirmed the decreased acute rejection and steroid resistant acute rejection rates shown in the prior randomized multicenter international trial comparing rATG-thymoglobulin to basiliximab in a population of moderate and high-risk patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/10\">",
"     10",
"    </a>",
"    ]. This trial in truly high-risk patients also showed a lower rate of delayed graft function in recipients of rATG-thymoglobulin compared to daclizumab (31 versus 45 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OKT3",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic OKT3 appears to be most effective in high-risk deceased donor kidney transplant recipients, including those who are sensitized, have 2 HLA-DR mismatches, or prolonged cold ischemia time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. However, OKT3 must be used with care because of a number of important acute side effects, particularly infection and a common first-dose reaction.",
"   </p>",
"   <p>",
"    Because of these side effects and the availability of better options, the use in the United States of OKT3 as induction therapy has decreased dramatically. In 2007, for example, OKT3 was used in only approximately one percent of the renal transplants in the United States for which information was available . Because of declining use, production ceased in June 2009 and the manufacturer estimated that the product would only be available through 2010. At our institution, all remaining vials of OKT3 will expire as of July 31, 2010.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ALEMTUZUMAB",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     Alemtuzumab",
"    </a>",
"    (Campath-1H) is a humanized anti-CD52 panlymphocytic (both B and T cells) monoclonal antibody that is approved for treatment of chronic lymphocytic leukemia. We prefer rATG-thymoglobulin for induction therapy in part because this agent has been much more rigorously studied over many decades. Alemtuzumab has been associated in some studies with more prolonged lymphopenia, autoimmune disease, and increased risk of infections as well as unusual forms of rejection.",
"   </p>",
"   <p>",
"    With respect to induction therapy in kidney transplant recipients, the dose and frequency of administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    , and optimal maintenance immunosuppressive regimen to be utilized with this agent remain to be determined. Some, but not all, centers use single dose administration.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     Alemtuzumab",
"    </a>",
"    is increasingly being used for induction therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/43-60\">",
"     43-60",
"    </a>",
"    ]. A number of observational studies and a few randomized controlled trials have been performed in kidney transplant recipients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial (INTAC), 139 high-risk patients (risk defined by a repeat transplant, panel reactive antibodies &gt;20 percent, or black race) were treated with one 30 mg dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      or rATG-thymoglobulin, 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      over four days, and 355 low-risk patients received one 30 mg dose of alemtuzumab or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22374?source=see_link\">",
"       basiliximab",
"      </a>",
"      40 mg over four days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/60\">",
"       60",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In the high-risk group, there was no difference in acute rejection in patients who received alemtuzumab compared with rATG-thymoglobulin at 6, 12 and 36 months (6 versus 9, 10 versus 13 and 18 versus 15 percent, respectively). In high-risk patients, late acute rejection (defined as rejection that occurred between 12 and 36 months in patients who did not have acute rejection in the first 12 months) was more common with alemtuzumab but this was not statistically significant (10 versus 2 percent, p=0.13), meaning that the trial was underpowered to detect a difference of this magnitude. A possible explanation of the lack of significant benefit, as others have documented, is that the beneficial effect of alemtuzumab decreases over time.",
"     </li>",
"     <li>",
"      In the low-risk group, the rate of acute rejection was lower in patients who received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      compared with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22374?source=see_link\">",
"       basiliximab",
"      </a>",
"      at 6, 12, and 36 months (2 versus 18, 3 versus 20, and 10 versus 22 percent). Late rejection was more common in the alemtuzumab compared to the basiliximab group (8 versus 3 percent). This confirms previous studies that showed that among low-risk patients, alemtuzumab is associated with less acute rejection early after transplantation but this effect attenuates over time; this is similar to the attenuation that was observed in the high risk population compared to rATG-thymoglobulin.",
"      <br/>",
"      <br/>",
"      In the low-risk group, there were no differences between alemtuzumab and basiliximab in patient survival, overall or death-censored graft survival, or in the overall rate of adverse effects but these studies were not powered to detect such differences. Among low-risk patients, compared to basiliximab, alemtuzumab was associated with a lower mean lymphocyte count at all time points; among high risk patients, rATG-thymoglobulin and alemtuzumab both caused a low mean lymphocyte count within the first week after transplantation.",
"     </li>",
"     <li>",
"      In another randomized controlled trial, the administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      permitted some transplant recipients to be maintained on less intense maintenance immunosuppressive therapy, including very low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      alone, or steroid-free regimens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/48\">",
"       48",
"      </a>",
"      ]. In this trial, ninety renal transplant recipients were randomly assigned to rATG-thymoglobulin (group A), alemtuzumab (group B), or daclizumab (group C). All three arms subsequently received tacrolimus and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil, but maintenance steroid therapy was only given to patients in groups A and C. Target levels for tacrolimus and mycophenolate were also lower in group B. At a median period of 15 months, patient and allograft survival rates, as well as acute rejection rates were similar in all groups.",
"      <br/>",
"      <br/>",
"      Follow-up at 48 months showed that group B (alemtuzumab without steroids) had worse death-censored graft survival compared to the other groups (78 versus 95 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/61\">",
"       61",
"      </a>",
"      ]. Chronic allograft nephropathy was also more common (37 versus 11 to 14 percent).",
"     </li>",
"     <li>",
"      There are also two randomized clinical trials performed by the same investigative group that evaluated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      or rATG-thymoglobulin as induction therapy in kidney, kidney-pancreas, and pancreas transplant recipients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/62,63\">",
"       62,63",
"      </a>",
"      ]. Although there was a suggestion of decreased rejection rates with alemtuzumab, these results are difficult to interpret since there are multiple limitations and flaws with these trials. These include enrollment of three different patient populations, variable dosing regimens, and randomization that was not done a priori.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are a number of reports of the induction of autoimmune disease, such as thrombocytopenia and autoimmune thyroid disease, with the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. A postulated mechanism is the expansion of memory T-cells after alemtuzumab-induced depletion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/66\">",
"     66",
"    </a>",
"    ]. Despite these observations, this agent does not appear to increase the risk of recurrent kidney disease in kidney transplant recipients with a history of glomerulonephritis, compared to the use of IL-2 receptor antagonists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H264090544\">",
"    <span class=\"h1\">",
"     AUTOLOGOUS MESENCHYMAL STEM CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autologous stem cell transplantation has been studied as a replacement for antibody induction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/67\">",
"     67",
"    </a>",
"    ]. In one open-label randomized trial, infusion of marrow-derived stem cells at the time of transplantation and two weeks after transplantation was compared with the administration of IL-2 receptor antagonists (control) among 104 recipients of ABO-compatible kidneys from living related donors. All patients received similar doses of calcineurin inhibitors,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil and glucocorticoids. There was no difference between groups in patient or graft survival at 13 to 30 months. At 6 months, there was a lower incidence of acute rejection among patients who received stem cell infusion compared with controls (7.5 versus 21.6 percent, respectively). Among 52 additional patients who received stem cell transplantation plus a 20 percent lower dose of calcineurin inhibitor there was a similarly decreased incidence of rejection compared with control (7.7 versus 21.6 percent, respectively). At one year there was a lower risk of opportunistic infections associated with stem cell transplantation compared with control (hazard ratio 0.42). Long term studies are required to address overall utility and safety of stem cell transplantation as induction therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     UNITED STATES TRENDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of use of the different immunosuppressive antilymphocyte regimens for induction therapy has varied markedly over the last 15 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/68\">",
"     68",
"    </a>",
"    ]. In 2011, the following frequency of use of different agents used for induction in the United States was noted for kidney transplant recipients about whom information was available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32649/abstract/69\">",
"     69",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      T cell depleting antibodies &ndash; 58 percent",
"     </li>",
"     <li>",
"      Il-2 receptor antibodies and T cell depleting antibodies &ndash; 4 percent",
"     </li>",
"     <li>",
"      Il-2 receptor antibodies &ndash; 22 percent",
"     </li>",
"     <li>",
"      None &ndash; 17 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend the administration of immunosuppressive therapy to renal allograft recipients (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The optimal immunosuppressive regimen is unclear. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview of our approach to induction therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients receiving a kidney allograft, we recommend induction therapy that consists of an antibody plus standard immunosuppressive therapy rather than standard immunosuppressive therapy alone (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Caucasian recipients of two haplotype-identical living related allografts do not generally require induction therapy with antibody therapy given the decreased immunologic risk of acute rejection. Antibodies include rATG-thymoglobulin, ATGAM,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      , OKT3, and two interleukin-2 receptor antibodies:",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22374?source=see_link\">",
"       basiliximab",
"      </a>",
"      and daclizumab. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Immunosuppressive antibody therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients at increased risk of rejection, we recommend the administration of rATG-thymoglobulin rather than an interleukin-2 receptor antagonist (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Among patients not at increased risk of rejection, we suggest the administration of rATG-thymoglobulin rather than an interleukin-2 receptor antagonist (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Polyclonal antibodies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients in whom rATG-thymoglobulin cannot be administered, we recommend the administration of an interleukin-2 receptor antibody (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'IL-2 receptor antibodies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/1\">",
"      Kahan BD. Individuality: the barrier to optimal immunosuppression. Nat Rev Immunol 2003; 3:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/2\">",
"      Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 Suppl 3:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/3\">",
"      Webster AC, Playford EG, Higgins G, et al. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 2004; 77:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/4\">",
"      Szczech LA, Berlin JA, Aradhye S, et al. Effect of anti-lymphocyte induction therapy on renal allograft survival: a meta-analysis. J Am Soc Nephrol 1997; 8:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/5\">",
"      Szczech LA, Berlin JA, Feldman HI. The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Anti-Lymphocyte Antibody Induction Therapy Study Group. Ann Intern Med 1998; 128:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/6\">",
"      Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998; 338:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/7\">",
"      Starzl TE, Murase N, Abu-Elmagd K, et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003; 361:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/8\">",
"      Kirk AD. Induction immunosuppression. Transplantation 2006; 82:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/9\">",
"      Webster AC, Ruster LP, McGee R, et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev 2010; :CD003897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/10\">",
"      Brennan DC, Daller JA, Lake KD, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006; 355:1967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/11\">",
"      Hardinger KL, Brennan DC, Schnitzler MA. Rabbit antithymocyte globulin is more beneficial in standard kidney than in extended donor recipients. Transplantation 2009; 87:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/12\">",
"      Miller JT, Collins CD, Stuckey LJ, et al. Clinical and economic outcomes of rabbit antithymocyte globulin induction in adults who received kidney transplants from living unrelated donors and received cyclosporine-based immunosuppression. Pharmacotherapy 2009; 29:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/13\">",
"      Wiland AM, Fink JC, Weir MR, et al. Should living-unrelated renal transplant recipients receive antibody induction? Results of a clinical experience trial. Transplantation 2004; 77:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/14\">",
"      Bonnefoy-B&eacute;rard N, Vincent C, Revillard JP. Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. Transplantation 1991; 51:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/15\">",
"      Bourdage JS, Hamlin DM. Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation 1995; 59:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/16\">",
"      Brennan DC, Flavin K, Lowell JA, et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999; 67:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/17\">",
"      Hardinger KL, Schnitzler MA, Miller B, et al. Five-year follow up of thymoglobulin versus ATGAM induction in adult renal transplantation. Transplantation 2004; 78:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/18\">",
"      Hardinger KL, Rhee S, Buchanan P, et al. A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results. Transplantation 2008; 86:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/19\">",
"      Benvenisty AI, Tannenbaum GA, Cohen DJ, et al. Use of antithymocyte globulin and cyclosporine to treat steroid-resistant rejection episodes in renal transplant recipients. Transplant Proc 1987; 19:1889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/20\">",
"      O'Donoghue DJ, Johnson RW, Mallick NP, et al. Rabbit anti-thymocyte globulin treatment of steroid resistant rejection in renal allograft recipients immunosuppressed with cyclosporine A. Transplant Proc 1989; 21:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/21\">",
"      Filo RS, Smith EJ, Leapman SB. Reversal of acute renal allograft rejection with adjunctive AG therapy. Transplant Proc 1981; 13:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/22\">",
"      Gaber AO, First MR, Tesi RJ, et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation 1998; 66:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/23\">",
"      Hardinger KL, Schnitzler MA, Koch MJ, et al. Thymoglobulin induction is safe and effective in live-donor renal transplantation: a single center experience. Transplantation 2006; 81:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/24\">",
"      Agha IA, Rueda J, Alvarez A, et al. Short course induction immunosuppression with thymoglobulin for renal transplant recipients. Transplantation 2002; 73:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/25\">",
"      Shapiro R, Jordan ML, Basu A, et al. Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg 2003; 238:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/26\">",
"      Goggins WC, Pascual MA, Powelson JA, et al. A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients. Transplantation 2003; 76:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/27\">",
"      Ruggenenti P, Codreanu I, Cravedi P, et al. Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: a possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation. Clin J Am Soc Nephrol 2006; 1:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/28\">",
"      Peddi VR, Bryant M, Roy-Chaudhury P, et al. Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients. Transplantation 2002; 73:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/29\">",
"      Stratta RJ, Sundberg AK, Farney AC, et al. Experience with alternate-day thymoglobulin induction in pancreas transplantation with portal-enteric drainage. Transplant Proc 2005; 37:3546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/30\">",
"      Wong W, Agrawal N, Pascual M, et al. Comparison of two dosages of thymoglobulin used as a short-course for induction in kidney transplantation. Transpl Int 2006; 19:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/31\">",
"      Gurk-Turner C, Airee R, Philosophe B, et al. Thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients. Transplantation 2008; 85:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/32\">",
"      Stevens RB, Mercer DF, Grant WJ, et al. Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report. Transplantation 2008; 85:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/33\">",
"      Pr&eacute;ville X, Flacher M, LeMauff B, et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 2001; 71:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/34\">",
"      Brennan DC, Schnitzler MA. Long-term results of rabbit antithymocyte globulin and basiliximab induction. N Engl J Med 2008; 359:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/35\">",
"      Knight RJ, Kerman RH, Schoenberg L, et al. The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function. Transplantation 2004; 78:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/36\">",
"      Mourad G, Rostaing L, Legendre C, et al. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 2004; 78:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/37\">",
"      Willoughby LM, Schnitzler MA, Brennan DC, et al. Early outcomes of thymoglobulin and basiliximab induction in kidney transplantation: application of statistical approaches to reduce bias in observational comparisons. Transplantation 2009; 87:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/38\">",
"      Haririan A, Morawski K, Sillix DH, et al. Induction therapy with basiliximab versus Thymoglobulin in African-American kidney transplant recipients. Transplantation 2005; 79:716.",
"     </a>",
"    </li>",
"    <li>",
"     Novartis October 6, 2000 \"Dear Healthcare Provider\" letter.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/40\">",
"      No&euml;l C, Abramowicz D, Durand D, et al. Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol 2009; 20:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/41\">",
"      Schroeder TJ, First MR, Mansour ME, et al. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients. Am J Kidney Dis 1989; 14:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/42\">",
"      Norman, DJ, Kahana, L, Stuart, FP Jr, et al. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 1993; 55:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/43\">",
"      Calne R, Moffatt SD, Friend PJ, et al. Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999; 68:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/44\">",
"      Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003; 76:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/45\">",
"      Tan HP, Kaczorowski DJ, Basu A, et al. Living-related donor renal transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: a single center preliminary experience. Transplantation 2004; 78:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/46\">",
"      Watson CJ, Bradley JA, Friend PJ, et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years. Am J Transplant 2005; 5:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/47\">",
"      Vathsala A, Ona ET, Tan SY, et al. Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 2005; 80:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/48\">",
"      Ciancio G, Burke GW, Gaynor JJ, et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 2005; 80:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/49\">",
"      Morris PJ, Russell NK. Alemtuzumab (Campath-1H): a systematic review in organ transplantation. Transplantation 2006; 81:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/50\">",
"      Knechtle SJ, Fernandez LA, Pirsch JD, et al. Campath-1H in renal transplantation: The University of Wisconsin experience. Surgery 2004; 136:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/51\">",
"      Shapiro R, Basu A, Tan H, et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg 2005; 200:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/52\">",
"      Kaufman DB, Leventhal JR, Axelrod D, et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results. Am J Transplant 2005; 5:2539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/53\">",
"      Ciancio G, Burke GW, Gaynor JJ, et al. The use of Campath-1H as induction therapy in renal transplantation: preliminary results. Transplantation 2004; 78:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/54\">",
"      Tan HP, Kaczorowski DJ, Basu A, et al. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 2006; 6:2409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/55\">",
"      Ciancio G, Burke GW 3rd. Alemtuzumab (Campath-1H) in kidney transplantation. Am J Transplant 2008; 8:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/56\">",
"      Ciancio G, Burke GW, Gaynor JJ, et al. Campath-1H induction therapy in African American and Hispanic first renal transplant recipients: 3-year actuarial follow-up. Transplantation 2008; 85:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/57\">",
"      Ortiz J, Palma-Vargas J, Wright F, et al. Campath induction for kidney transplantation: report of 297 cases. Transplantation 2008; 85:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/58\">",
"      Tan HP, Donaldson J, Basu A, et al. Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up. Am J Transplant 2009; 9:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/59\">",
"      Pascual J, Mezrich JD, Djamali A, et al. Alemtuzumab induction and recurrence of glomerular disease after kidney transplantation. Transplantation 2007; 83:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/60\">",
"      Hanaway MJ, Woodle ES, Mulgaonkar S, et al. Alemtuzumab induction in renal transplantation. N Engl J Med 2011; 364:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/61\">",
"      Ciancio G, Burke GW, Gaynor JJ, et al. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up. Clin Transplant 2008; 22:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/62\">",
"      Farney A, Sundberg A, Moore P, et al. A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation. Clin Transplant 2008; 22:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/63\">",
"      Farney AC, Doares W, Rogers J, et al. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation. Transplantation 2009; 88:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/64\">",
"      Haider I, Cahill M. Fatal thrombocytopaenia temporally related to the administration of alemtuzumab (MabCampath) for refractory CLL despite early discontinuation of therapy. Hematology 2004; 9:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/65\">",
"      Kirk AD, Hale DA, Swanson SJ, Mannon RB. Autoimmune thyroid disease after renal transplantation using depletional induction with alemtuzumab. Am J Transplant 2006; 6:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/66\">",
"      Pearl JP, Parris J, Hale DA, et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005; 5:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/67\">",
"      Tan J, Wu W, Xu X, et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA 2012; 307:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32649/abstract/68\">",
"      Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant 2006; 6:1111.",
"     </a>",
"    </li>",
"    <li>",
"     www.ustransplant.org (Accessed January, 2010).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7353 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-519069B3B6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_56_32649=[""].join("\n");
var outline_f31_56_32649=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF OUR APPROACH TO INDUCTION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Immunosuppressive antibody therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nonimmunosuppressive components",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      POLYCLONAL ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      rATG-thymoglobulin versus ATGAM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      rATG-thymoglobulin compared with IL-2 receptor antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Dosing strategies for rATG-thymoglobulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      How we administer rATG-thymoglobulin in combination with maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      IL-2 RECEPTOR ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Efficacy of basiliximab compared with rATG-thymoglobulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Daclizumab versus rATG-thymoglobulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OKT3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ALEMTUZUMAB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H264090544\">",
"      AUTOLOGOUS MESENCHYMAL STEM CELLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      UNITED STATES TRENDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7353\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7353|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/50/18219\" title=\"table 1\">",
"      Induction in renal transplant",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/52/4938?source=related_link\">",
"      Acute renal allograft rejection: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34778?source=related_link\">",
"      Chronic renal allograft nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29738?source=related_link\">",
"      Cytomegalovirus infection in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/9/40084?source=related_link\">",
"      Differential diagnosis of infection following renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43706?source=related_link\">",
"      Maintenance immunosuppressive therapy in renal transplantation in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_56_32650="Spontaneous intracerebral hemorrhage: Prognosis and treatment";
var content_f31_56_32650=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Spontaneous intracerebral hemorrhage: Prognosis and treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/56/32650/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/56/32650/contributors\">",
"     Guy Rordorf, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/56/32650/contributors\">",
"     Colin McDonald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/56/32650/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/56/32650/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/56/32650/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/56/32650/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/56/32650/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracerebral hemorrhage (ICH) is the second most common cause of stroke, following ischemic stroke.",
"   </p>",
"   <p>",
"    The prognosis and treatment of spontaneous intracerebral hemorrhage will be reviewed here. Other aspects of ICH are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29130?source=see_link\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mortality and functional outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 30-day mortality from ICH ranges from 35 to 52 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/1-8\">",
"     1-8",
"    </a>",
"    ]; one-half of these deaths occur within the first two days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/3,7,9\">",
"     3,7,9",
"    </a>",
"    ]. Furthermore, only a small number of patients function independently after the event. In a prospective study of 166 patients with spontaneous ICH from a large US metropolitan area, only 12 percent were normal or minimally handicapped at 30 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/10\">",
"     10",
"    </a>",
"    ]. A systematic review estimated that between 12 and 39 percent of patients achieve independent function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis after ICH depends upon the location of hemorrhage (supra versus infratentorial location), size of the hematoma, level of consciousness, patient age, and overall medical health and condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/3,4,6,9,11-13\">",
"     3,4,6,9,11-13",
"    </a>",
"    ]. In addition, preceding oral anticoagulation therapy, and possibly antiplatelet therapy, appears to be associated with worse outcomes after ICH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/9,14\">",
"     9,14",
"    </a>",
"    ]. One study found that hemorrhage from a cerebral arteriovenous malformation were associated with a lower case-fatality rate, despite a similar hemorrhage volume and a higher admission Glasgow coma scale compared with spontaneous ICH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/15\">",
"     15",
"    </a>",
"    ]. Mortality was also reported to be low (1 of 22) in a cohort of children with ICH in whom vascular malformations was the identified etiology in 91 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term survival after primary ICH also appears to be decreased compared with controls from the general population matched for age and sex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/4,6,17\">",
"     4,6,17",
"    </a>",
"    ]. A retrospective cohort study identified 411 patients with first ever ICH and found that the annual risk of dying compared with controls was increased 4.5-fold during the first year after ICH and 2.2-fold during years two to six [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/4\">",
"     4",
"    </a>",
"    ]. A subsequent longitudinal prospective cohort study evaluated patients who had survived the first three months after ICH and observed that the mortality at seven years was significantly higher than controls (32.9 versus 19.4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/17\">",
"     17",
"    </a>",
"    ]. In a population-based cohort of patients hospitalized after ICH in the Greater",
"    <span class=\"nowrap\">",
"     Cincinnati/Northern",
"    </span>",
"    Kentucky area, the ten-year survival was 18 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Initial ICH volume and level of consciousness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ICH volume on initial head CT scan and level of consciousness on admission may be particularly important prognostic indicators [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/3,18\">",
"     3,18",
"    </a>",
"    ]. This point is illustrated by a study of 188 patients with ICH that analyzed predictors of 30-day mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/3\">",
"     3",
"    </a>",
"    ]; the following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An ICH volume of 60 cm3 or greater on initial CT and a Glasgow coma scale score (",
"      <a class=\"graphic graphic_table graphicRef81854 \" href=\"mobipreview.htm?28/62/29676\">",
"       table 1",
"      </a>",
"      ) of eight or less predicted a 30-day mortality of 91 percent.",
"     </li>",
"     <li>",
"      An ICH volume less than 30 cm3 and a Glasgow coma scale score of nine or more predicted a 30-day mortality of 19 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The method for calculating ICH volume from head CT is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29130?source=see_link&amp;anchor=H18#H18\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\", section on 'Head CT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Hematoma growth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematoma growth, particularly within the first 24 hours, is also an independent predictor of mortality and poor outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/19\">",
"     19",
"    </a>",
"    ]. In a meta-analysis of 218 patients with spontaneous ICH who had a head CT scan within three hours of onset and follow-up head CT within 24 hours, each 10 percent increase in ICH growth was associated with increased mortality (hazard ratio 1.05, 95% CI 1.03-1.08) and worse outcome as measured by the modified Rankin scale (odds ratio 0.84, 95% CI 0.75-0.92) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/20\">",
"     20",
"    </a>",
"    ]. That is, for each 10 percent increase in hematoma volume, patients were 5 percent more likely to die and 16 percent more likely to increase one point on the modified Rankin scale (",
"    <a class=\"graphic graphic_table graphicRef75411 \" href=\"mobipreview.htm?22/32/23051\">",
"     table 2",
"    </a>",
"    ). A subsequently published analysis found that while all measures of hematoma growth are robust predictors of worse outcomes, absolute increases in hemorrhage volume have higher predictive values compared with relative increases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors for hematoma enlargement (contrast extravasation or &ldquo;spot sign&rdquo; on CTA, blood pressure, antithrombotic therapy) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29130?source=see_link&amp;anchor=H6#H6\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\", section on 'Hemorrhage enlargement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Intraventricular extension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from a number of studies suggest that extension of blood into the ventricles is an independent predictor of poor outcome in patients with spontaneous ICH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/22-27\">",
"     22-27",
"    </a>",
"    ]. One of the largest of these reports evaluated 406 patients with ICH, 45 percent of whom had intraventricular extension of hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/26\">",
"     26",
"    </a>",
"    ]. After controlling for age and ICH volume, a poor outcome at discharge (defined as a modified Rankin scale score of 4 to 6 (",
"    <a class=\"graphic graphic_table graphicRef75411 \" href=\"mobipreview.htm?22/32/23051\">",
"     table 2",
"    </a>",
"    )) was significantly more likely in patients with intraventricular hemorrhage than in those without intraventricular hemorrhage (odds ratio 2.25, 95% CI 1.40-3.64).",
"   </p>",
"   <p>",
"    Intraventricular hemorrhage is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/55/6009?source=see_link\">",
"     \"Intraventricular hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Early neurologic deterioration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early neurologic deterioration within 48 hours after ICH onset is not infrequent and is associated with a poor prognosis. Potential mechanisms include hemorrhage enlargement, development of hydrocephalus, and perilesional edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/19,28\">",
"     19,28",
"    </a>",
"    ]. The inflammatory response to the hemorrhage may also play a role.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a cohort study of 266 patients with ICH admitted within 12 hours of stroke onset, early neurologic deterioration occurred in 61 (23 percent) and was associated with an eight-fold increase in the probability of a poor outcome (95% CI 2.7-25.5) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/29\">",
"       29",
"      </a>",
"      ]. Independent predictors of early neurologic deterioration on admission included elevations in body temperature, neutrophil count, and serum fibrinogen level (odds ratios 24.5, 2.1, and 5.6, respectively), all of which could be interpreted as markers of an inflammatory response. Factors measured at 48 hours that were associated with early neurologic deterioration included ICH growth on repeat head CT, intraventricular bleeding, and high systolic blood pressure.",
"     </li>",
"     <li>",
"      In many [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/9,28,30,31\">",
"       9,28,30,31",
"      </a>",
"      ] but not all [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/29\">",
"       29",
"      </a>",
"      ] reports, the initial ICH volume on CT is an independent predictor of early deterioration. The degree and subsequent expansion of perilesional edema is strongly related to the size of the initial ICH volume, and at least in one study, did not appear have an independent effect in predicting outcome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Preceding antithrombotic use",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of an acute ICH, patients with preceding use of anticoagulants or antiplatelet agents might be expected to have larger initial hematoma volumes or greater hemorrhage enlargement leading to worse outcomes. Accumulating evidence suggests that this notion may be correct, at least with regard to anticoagulants. However, the issue is not simple, as patients receiving these therapies may be older and have greater comorbidities than those who are not. In addition, the available evidence is mainly observational.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3373984\">",
"    <span class=\"h4\">",
"     Oral anticoagulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients on oral anticoagulant therapy have a mortality rate of 52 to 73 percent after ICH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/14,33-35\">",
"     14,33-35",
"    </a>",
"    ]. Furthermore, ICH related to oral anticoagulant therapy is associated with a worse outcome than spontaneous ICH, as illustrated by the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study that analyzed data from 303 patients in the placebo arm of a prospective trial of a putative neuroprotective drug for ICH, there were 21 patients receiving oral anticoagulants at the time of ICH onset [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/35\">",
"       35",
"      </a>",
"      ]. Patients with oral anticoagulant-related ICH had a significantly higher mortality rate at 90 days than those with spontaneous ICH (62 versus 17 percent). In addition, the proportion of patients with hemorrhage expansion at 72 hours was significantly higher among those with anticoagulant-related ICH (56 versus 26 percent). On multivariate analysis, oral anticoagulant use was independently associated with both hemorrhage expansion and mortality.",
"     </li>",
"     <li>",
"      A population-based study from northern Finland reported that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      use at the onset of ICH was an independent risk factor for death within three months of ICH (relative risk [RR] 3.2; 95% CI 1.6-6.1) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3374003\">",
"    <span class=\"h4\">",
"     Antiplatelets",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence regarding preceding antiplatelet use with prognosis after ICH is not as clear, with some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/14,36-38\">",
"     14,36-38",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/34,39-43\">",
"     34,39-43",
"    </a>",
"    ] studies reporting worse prognosis or greater hematoma enlargement with ICH. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A population-based study from Finland reported that regular",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      use at the onset of ICH was a significant independent risk factor for death within three months of ICH (RR 2.5; 95% CI 1.3-4.6) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the placebo arm of the CHANT trial, use of antiplatelet agents at the time of ICH was not associated with initial ICH volume or subsequent ICH expansion, nor did it impact 90 day clinical outcome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A systematic review of 25 cohort studies (that did not include the CHANT trial above) concluded that prior antiplatelet use was associated with increased mortality (OR = 1.3), but not poor functional outcome after ICH [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     ICH score",
"    </span>",
"    &nbsp;&mdash;&nbsp;A simple six-point clinical grading scale called the ICH score has been devised to predict mortality after ICH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/45\">",
"     45",
"    </a>",
"    ]. This scale incorporates several clinical components that may be independent predictors of outcome.",
"   </p>",
"   <p>",
"    The ICH score is determined by adding the score from each component as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glasgow Coma Scale (GCS) score 3 to 4 (= 2 points); GCS 5 to 12 (= 1 point) and GCS 13 to 15 (= 0 points) (",
"      <a class=\"graphic graphic_table graphicRef81854 \" href=\"mobipreview.htm?28/62/29676\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      ICH volume &ge;30 cm3 (= 1 point), ICH volume &lt;30 cm3 (= 0 points)",
"     </li>",
"     <li>",
"      Intraventricular extension of hemorrhage present (= 1 point); absent (= 0 points)",
"     </li>",
"     <li>",
"      Infratentorial origin yes (= 1 point); no (= 0 points)",
"     </li>",
"     <li>",
"      Age &ge;80 (= 1 point); &lt;80 (= 0 points)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thirty-day mortality rates increased steadily with ICH score; mortality rates for ICH scores of 1, 2, 3, 4, and 5 were 13, 26, 72, 97, and 100 percent, respectively. No patient with an ICH score of 0 died, and none had a score of 6 in the cohort.",
"   </p>",
"   <p>",
"    The ICH score has been validated by retrospective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/46\">",
"     46",
"    </a>",
"    ] and prospective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/47,48\">",
"     47,48",
"    </a>",
"    ] analysis. A modified ICH score [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/46\">",
"     46",
"    </a>",
"    ] using the National Institutes of Health Stroke Scale (NIHSS) score [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/49\">",
"     49",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef61698 \" href=\"mobipreview.htm?39/33/40477\">",
"     table 3",
"    </a>",
"    ) in place of the GCS score may be a better predictor of good outcome than the original ICH score.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Limiting care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prognostication for individual patients with acute ICH remains an uncertain science at best. Accumulating data suggest that the early use of do not resuscitate (DNR) orders, along with decisions to limit aggressive treatments",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    withdraw medical care may negatively influence outcome in patients with ICH, and may even invalidate some prognostic models that do not control for this variable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/50-54\">",
"     50-54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early DNR orders or limitations to care are not always inappropriate after ICH; the difficulty lies in deciding when such limitations are indeed the most appropriate approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Current guidelines suggest careful consideration of aggressive full care during the first 24 hours after ICH onset and postponement of new DNR orders during that time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/12,55\">",
"     12,55",
"    </a>",
"    ]. The recommendation does not apply to patients with preexisting DNR orders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient age and overall medical health and condition have an important role in the patient&rsquo;s survival and morbidity after ICH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of reports have noted that elevated admission blood glucose after ICH is a poor prognostic indicator [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/4,9,57-61\">",
"     4,9,57-61",
"    </a>",
"    ]. However, it is unclear if elevated glucose directly contributes to poor outcome, or if it alternatively is present secondarily as part of the stress response to severe ICH.",
"   </p>",
"   <p>",
"    Low total and LDL cholesterol have been linked to a risk of ICH. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29130?source=see_link&amp;anchor=H8#H8\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\", section on 'Risk factors'",
"    </a>",
"    .) In one study of 108 patients with ICH, lower serum LDL-cholesterol predicted early hematoma growth, neurologic deterioration, and three-month mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study found that patients with more extensive white matter lesions assessed on admission CT scan had a higher rate of mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/63\">",
"     63",
"    </a>",
"    ]. Another study found that elevated C-reactive protein levels were an independent predictor of mortality after ICH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of studies have found that a significant number of patients with ICH have acute ischemic lesions on diffusion-weighted MRI imaging that are not contiguous to the hematoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/65\">",
"     65",
"    </a>",
"    ]. The implication for these findings for prognosis are as yet undefined, although one study found that the presence of these lesions were associated with increased odds of death and disability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent hypertensive ICH occurs in as many as 5 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/7,67-69\">",
"     7,67-69",
"    </a>",
"    ]. Recurrence is most common within two years of the first hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/68\">",
"     68",
"    </a>",
"    ], with the most important risk factor being uncontrolled hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/67\">",
"     67",
"    </a>",
"    ]. In one study with a three-year follow-up, the risk for subsequent cerebral infarction was similar to the risk of recurrent hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors for recurrent ICH include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/55\">",
"     55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Uncontrolled hypertension",
"     </li>",
"     <li>",
"      Lobar location of initial ICH",
"     </li>",
"     <li>",
"      Older age",
"     </li>",
"     <li>",
"      Ongoing anticoagulation",
"     </li>",
"     <li>",
"      Apolipoprotein E epsilon 2 or epsilon 4 alleles",
"     </li>",
"     <li>",
"      Greater number of microbleeds on MRI",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of intracerebral hemorrhage (ICH) involves a combination of medical and surgical interventions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/12,70\">",
"     12,70",
"    </a>",
"    ]. Guidelines from the American Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    Stroke Association",
"    <span class=\"nowrap\">",
"     (AHA/ASA)",
"    </span>",
"    issued in 2007 recommend that patients with ICH receive monitoring and management in an intensive care unit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/12\">",
"     12",
"    </a>",
"    ]. This recommendation is based upon the frequent association of ICH with elevations in intracranial pressure and blood pressure, the need for intubation and mechanical ventilation, and multiple medical issues and complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     General management issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial general management of patients with suspected stroke is briefly summarized here [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/12,61\">",
"     12,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sources of fever should be treated, and current guidelines suggest the use of antipyretic medications to lower body temperature to normothermia in febrile patients with stroke [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/12,55\">",
"       12,55",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/29/33242?source=see_link&amp;anchor=H12#H12\">",
"       \"Initial assessment and management of acute stroke\", section on 'Fever'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyperglycemia in the first 24 hours after stroke is associated with adverse outcomes, and current guidelines suggest insulin treatment for elevated serum glucose &gt;140 to 185",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&gt;7.8 to 10.3",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/12,55\">",
"       12,55",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/29/33242?source=see_link&amp;anchor=H100191613#H100191613\">",
"       \"Initial assessment and management of acute stroke\", section on 'Hyperglycemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Options for the prevention of venous thromboembolism and deep venous thrombosis in patients with ICH include intermittent pneumatic compression, low-dose subcutaneous low molecular weight",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , unfractionated heparin, and placement of a vena cava filter [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/12,55\">",
"       12,55",
"      </a>",
"      ]. These options are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/57/8089?source=see_link\">",
"       \"Anticoagulant and antiplatelet therapy in patients with an acute or prior intracerebral hemorrhage\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Early mobilization and rehabilitation are suggested in patients with ICH who are clinically stable [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/12,55\">",
"       12,55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Reversal of anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who develop an ICH, all anticoagulant and antiplatelet drugs should be discontinued acutely for at least one to two weeks after the onset of hemorrhage, and anticoagulant effect should be reversed immediately with appropriate agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/12,71\">",
"     12,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aggressive use of intravenous vitamin K, unactivated prothrombin complex concentrate (also called factor IX complex), and other factors may be necessary in patients who suffer an ICH while taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . Reversal of anticoagulation in this setting is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10298?source=see_link&amp;anchor=H6#H6\">",
"     \"Management of warfarin-associated intracerebral hemorrhage\", section on 'Reversing the coagulation defect'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is a risk of creating a prothrombotic state when acutely reversing anticoagulation in a patient with atrial fibrillation; however, the risk of extending the hemorrhage outweighs this potential risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/9/11413?source=see_link\">",
"     Protamine sulfate",
"    </a>",
"    is recommended for urgent treatment of patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -associated ICH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/12,71\">",
"     12,71",
"    </a>",
"    ]. Protamine sulfate can be administered by slow intravenous infusion (not greater than 20",
"    <span class=\"nowrap\">",
"     mg/min",
"    </span>",
"    and no more than 50 mg over any 10-minute period). The appropriate dose of protamine sulfate is dependent upon the dose of heparin given and the time elapsed since that dose. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=see_link&amp;anchor=H23#H23\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Heparin reversal with protamine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with severe coagulation factor deficiency or thrombocytopenia should receive appropriate factor replacement or platelet transfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20586?source=see_link&amp;anchor=H558384432#H558384432\">",
"     \"Clinical and laboratory aspects of platelet transfusion therapy\", section on 'Indications for platelet transfusion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Intracranial pressure control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased intracranial pressure (ICP) due to ICH can result from the hematoma itself and from surrounding edema, and may contribute to brain injury and neurologic deterioration. Current guidelines recommend a balanced and graded approach to the management of elevated ICP, beginning with simple measures that include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevate the head of the bed to 30 degrees, once hypovolemia is excluded.",
"     </li>",
"     <li>",
"      Analgesia and sedation, particularly in unstable, intubated patients",
"      <br/>",
"      <br/>",
"      Sedation should be titrated to control pain and minimize ICP elevation, while still permitting clinical evaluation of the patient's neurologic status [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/12\">",
"       12",
"      </a>",
"      ]. Suggested intravenous agents for sedation are",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"       propofol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"       etomidate",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"       midazolam",
"      </a>",
"      . Suggested agents for analgesia and antitussive effect are",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/9/3223?source=see_link\">",
"       alfentanil",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/29/15833?source=see_link\">",
"       \"Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Glucocorticoids should not generally be used to lower the ICP in patients with ICH. A randomized trial found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    did not improve outcome but did increase complication rates, primarily infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Aggressive measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitoring and treatment of ICP should be considered for patients with GCS &lt;8, those with clinical evidence of transtentorial herniation, or those with significant IVH or hydrocephalus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/55\">",
"     55",
"    </a>",
"    ]. More aggressive therapies for reducing elevated ICP include osmotic diuretics (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    and hypertonic saline solution), ventricular catheter drainage of cerebrospinal fluid, and neuromuscular blockade with the goal of maintaining cerebral perfusion pressure (CPP) of 50 to 70 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/12,55\">",
"     12,55",
"    </a>",
"    ]. However, the development of cerebral ischemia is still possible even with CPP-guided therapy.",
"   </p>",
"   <p>",
"    CPP equals mean arterial pressure (MAP) minus ICP. Lowering ICP helps to maintain CPP in an adequate range. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=see_link\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      is the treatment of choice to lower increased intracranial pressure, effectively lowering ICP and benefiting brain metabolism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/74\">",
"       74",
"      </a>",
"      ]. It is administered as an initial bolus of 1",
"      <span class=\"nowrap\">",
"       g/kg,",
"      </span>",
"      followed by infusions of 0.25 to 0.5",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      every six hours. The goal of therapy is to achieve plasma hyperosmolality (300 to 310",
"      <span class=\"nowrap\">",
"       mosmol/kg)",
"      </span>",
"      while maintaining an adequate plasma volume; major side effects include hypovolemia and a hyperosmotic state [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/12\">",
"       12",
"      </a>",
"      ]. Normal saline initially should be used for maintenance and replacement fluids; hypotonic fluids are contraindicated. Mild hypernatremia should be tolerated, but marked hyperosmolality should be avoided to prevent precipitation of acute renal failure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/75\">",
"       75",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32451?source=see_link\">",
"       \"Complications of mannitol therapy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/29/41430?source=see_link\">",
"       \"Serum osmolal gap\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Barbiturate anesthesia can be used if",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      fails to lower ICP to an acceptable range. Barbiturate coma acts by reducing cerebral metabolism, which results in a lowering of cerebral blood flow and thus decreases ICP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/12\">",
"       12",
"      </a>",
"      ]. It is of variable benefit for the treatment of elevated ICP from a variety of causes and is associated with a high rate of severe side effects, especially arterial hypotension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/76\">",
"       76",
"      </a>",
"      ]. Continuous electroencephalogram monitoring is suggested during high-dose barbiturate treatment, with the dose titrated to a burst-suppression pattern of electrical activity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The ICP lowering effect of hyperventilation to a PaCO2 of 25 to 30 mmHg is dramatic and rapid. However, the effect only lasts for minutes to a few hours. Thus, we reserve hyperventilation until the above therapies have been maximized [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Neuromuscular blockade is sometimes employed to reduce ICP in patients who are not responsive to analgesia and sedation alone, as muscle activity can contribute to increased ICP by raising intrathoracic pressure, thereby reducing cerebral venous outflow [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/12\">",
"       12",
"      </a>",
"      ]. Drawbacks of neuromuscular blockade include an increased risk of pneumonia and sepsis. In addition, the ability to evaluate the neurologic status is lost once the patient is paralyzed. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/44/43720?source=see_link\">",
"       \"Use of neuromuscular blocking medications in critically ill patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cerebrospinal fluid drainage by intraventricular catheter placement (ventriculostomy) is an effective means of lowering ICP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/12\">",
"       12",
"      </a>",
"      ]. However, there are no prospective studies. Ventriculostomy is often used in the setting of obstructive hydrocephalus, which is a common complication of thalamic hemorrhage with third ventricle compression, and of cerebellar hemorrhage with fourth ventricle compression.",
"      <br/>",
"      <br/>",
"      Ventriculostomy allows a means of both monitoring ICP and relieving hydrocephalus. Some patients will develop communicating hydrocephalus and require a ventriculoperitoneal shunt. Available evidence suggests its use is associated with high rates of morbidity and mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/78,79\">",
"       78,79",
"      </a>",
"      ]. Infectious complications include bacterial colonization in 0 to 19 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/80,81\">",
"       80,81",
"      </a>",
"      ] and bacterial meningitis in 6 to 22 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/81,82\">",
"       81,82",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Blood pressure control",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mean arterial pressure (MAP) is often elevated in patients with ICH. Severe elevations in blood pressure may worsen ICH by representing a continued force for bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/83\">",
"     83",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29130?source=see_link&amp;anchor=H6#H6\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\", section on 'Hemorrhage enlargement'",
"    </a>",
"    .) However, an increased MAP may be necessary to maintain cerebral perfusion in some patients, and lowering the arterial pressure (eg, to a systolic blood pressure [SBP] below 130 mmHg) may cause ischemia and worsen neurologic injury. Two observational studies have found that greater acute BP reductions are associated with increased incidence of areas of decreased diffusion on MRI scan, although the implication of these findings for prognosis is as yet undefined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/65,66,84\">",
"     65,66,84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limited prospective data are available regarding BP management in ICH. In a randomized controlled trial (INTERACT) of 404 patients with acute spontaneous ICH, intensive blood pressure lowering treatment (target systolic blood pressure 140 mmHg) compared with traditional management (target SBP 180 mmHg) was associated with a reduction in hematoma growth at 24 hours (14 versus 26 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. However, this finding did not achieve statistical significance after adjustment for initial hematoma volume and time from ICH onset to head CT. There was no effect of treatment on clinical outcomes at 90 days. Smaller, nonrandomized studies have also found that more aggressive BP lowering is associated with strong trends toward reduced hematoma enlargement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/12,86-88\">",
"     12,86-88",
"    </a>",
"    ]. In some studies, there were also trends toward reduced perilesional edema and better clinical outcomes. Larger trials (INTERACT2, ATACH II) are in progress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current guidelines for managing elevated blood pressure in acute spontaneous ICH are as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/12,55\">",
"     12,55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with SBP &gt;200 mmHg or MAP &gt;150 mmHg, consider aggressive reduction of blood pressure with continuous intravenous infusion of medication accompanied by frequent (every five minutes) blood pressure monitoring",
"     </li>",
"     <li>",
"      For patients with SBP &gt;180 mmHg or MAP &gt;130 mmHg and evidence or suspicion of elevated ICP, consider monitoring ICP and reducing blood pressure using intermittent or continuous intravenous medication to keep cerebral perfusion pressure in the range of 61 to 80 mmHg",
"     </li>",
"     <li>",
"      For patients with SBP &gt;180 mmHg or MAP &gt;130 mmHg and",
"      <strong>",
"       no",
"      </strong>",
"      evidence or suspicion of elevated ICP, consider a modest reduction of blood pressure (eg, target MAP of 110 mmHg or target blood pressure of",
"      <span class=\"nowrap\">",
"       160/90",
"      </span>",
"      mmHg) using intermittent or continuous intravenous medication, and clinically reexamine the patient every 15 minutes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These guidelines also concluded that in patients presenting with a SBP of 150 to 200 mm Hg, acute lowering of SBP to 140 mm Hg is probably safe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/55\">",
"     55",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35544?source=see_link\">",
"     Labetalol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/61/42969?source=see_link\">",
"     nicardipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/37/40536?source=see_link\">",
"     esmolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    are useful intravenous agents for controlling blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Seizure prophylaxis and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of seizures in patients with acute spontaneous ICH ranges from 4.2 to 29 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/12\">",
"     12",
"    </a>",
"    ]. Seizures are more common in lobar as compared to deep hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/89\">",
"     89",
"    </a>",
"    ]. The frequency depends in part on the extent of monitoring, as seizures associated with ICH are often nonconvulsive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29130?source=see_link&amp;anchor=H10#H10\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a seizure occurs, appropriate intravenous antiepileptic drug (AED) treatment should be administered to prevent recurrent seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/55\">",
"     55",
"    </a>",
"    ]. The choice of the initial antiepileptic agent depends upon individual circumstances and contraindications. Current guidelines suggest the use of intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/51/14138?source=see_link\">",
"     fosphenytoin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While some experts suggest a brief period of AED prophylaxis soon after ICH onset as a potential means of reducing the risk for early seizures in patients with lobar hemorrhages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/12\">",
"     12",
"    </a>",
"    ], 2010 guidelines recommend against prophylactic use of AEDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/55\">",
"     55",
"    </a>",
"    ] This strategy has not been tested prospectively in clinical trials. However, two case series have found that prophylactic treatment with AEDs was associated with poorer outcomes (a concern that has also been raised for subarachnoid hemorrhage patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. However these were a nonrandomized observational studies, and sample size did not allow for examination of a differential effect from different AEDs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for surgery in patients with ICH vary with the site of the bleed.",
"   </p>",
"   <p>",
"    Surgical removal of hemorrhage with cerebellar decompression should be performed for patients with cerebellar hemorrhages greater than 3 cm in diameter who are deteriorating, or who have brainstem compression",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hydrocephalus due to ventricular obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/12,55,92\">",
"     12,55,92",
"    </a>",
"    ]. Surgery decreases the risk of brainstem compression and obstructive hydrocephalus. External drainage alone, without posterior fossa decompression, may create the theoretical opportunity for upward herniation of the cerebellar mass and is not recommended.",
"   </p>",
"   <p>",
"    Surgical hematoma evacuation for supratentorial ICH is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/12,55,93-100\">",
"     12,55,93-100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis published in 1997 found insufficient data to draw conclusions regarding the",
"      <span class=\"nowrap\">",
"       risk/benefit",
"      </span>",
"      ratio of surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/93\">",
"       93",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In a small trial (n = 20), patients with ICH assigned to early surgery (the median time from onset of symptoms to surgery was 8.5 hours) showed a nonsignificantly higher rate of good outcome at three months than patients treated medically (56 and 36 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/101\">",
"       101",
"      </a>",
"      ]. In addition, surgery was associated with a statistically significant improvement in one of the secondary outcomes, the National Institutes of Health Stroke Scale (NIHSS) score (4 versus 14).",
"     </li>",
"     <li>",
"      Another small study of ultra early surgical evacuation was stopped prematurely because surgery within four hours of ICH symptom onset showed a trend towards increased rebleeding compared with surgery within 12 hours (40 versus 12 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/95\">",
"       95",
"      </a>",
"      ]. Postoperative rebleeding was significantly associated with increased mortality.",
"     </li>",
"     <li>",
"      In the STICH trial, patients assigned to early surgical hematoma evacuation (n = 503) were slightly more likely to have a favorable outcome at six months compared with initial conservative treatment (n = 530), but the trend did not reach statistical significance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/99\">",
"       99",
"      </a>",
"      ]. Benefit from early surgery was nonsignificantly more likely in patients who had craniotomy as opposed to alternate techniques, and in those with hematoma located 1 cm or less from the cortical surface.",
"      <br/>",
"      <br/>",
"      Although the STICH trial was designed to investigate the effectiveness of early surgery (within 24 hours of randomization), the STICH trial does not address the effectiveness of very early surgery in the first 12 hours after ICH onset [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/100,102,103\">",
"       100,102,103",
"      </a>",
"      ]. First, considerable delay to surgery was possible in the \"early surgery\" group, since patients were randomly assigned within 72 hours after hemorrhage onset and then treated within 24 hours after randomization; the median time to surgery in this group was 30 hours. In addition, the trial design permitted crossover to surgery in patients initially assigned to conservative medical management; such crossover occurred in 26 percent of the conservative group, mainly because of neurologic deterioration, at a mean time of 60 hours. Therefore, the trial more accurately assessed the surgical removal of ICH at about 30 hours versus initial medical management with or without delayed surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/103\">",
"       103",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 2008 meta-analysis reviewed 10 trials including 2059 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/104\">",
"       104",
"      </a>",
"      ]. Surgery was associated with a reduced risk of death and dependency (OR 0.71).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Open craniotomy is the most widely studied surgical techniques in patients with supratentorial ICH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/12\">",
"     12",
"    </a>",
"    ]. Other methods include endoscopic hemorrhage aspiration, use of fibrinolytic therapy to dissolve the clot followed by aspiration, and CT-guided stereotactic aspiration.",
"   </p>",
"   <p>",
"    Because of the questionable efficacy of surgery, it should only be considered as a life saving procedure to treat refractory increases in ICP; even in these instances, decisions should be addressed on a per patient basis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgery should not be considered for patients who are either fully",
"      <span class=\"nowrap\">",
"       alert/intact",
"      </span>",
"      or deeply comatose. Patients with intermediate levels of arousal (obtundation-stupor) are more appropriate candidates.",
"     </li>",
"     <li>",
"      Features that support performing surgery include a recent onset of hemorrhage, ongoing clinical deterioration, involvement of the nondominant hemisphere, and location of the hematoma near the cortical surface.",
"     </li>",
"     <li>",
"      Features in favor of less aggressive therapy include serious concomitant medical problems, advanced age, stable clinical condition, remote onset of hemorrhage, involvement of the dominant hemisphere, and inaccessibility of the hemorrhage",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with supratentorial ICH, current guidelines suggest consideration of standard craniotomy only for those who have lobar clots &gt;30 mL within 1 cm of the surface [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/12,55\">",
"     12,55",
"    </a>",
"    ]. No other patient group is recommended for surgery, and no surgical method other than standard craniotomy is supported. The routine evacuation of supratentorial ICH in the first 96 hours is not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2514292\">",
"    <span class=\"h2\">",
"     Intraventricular hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with intraventricular extension of the ICH are at risk for hydrocephalus, especially if the third and fourth ventricles are involved. Such patients should be closely monitored. When neurologic deterioration occurs, an emergent CT scan should be done to exclude the development of hydrocephalus. Patients with neurologic deterioration in the setting of ventricular enlargement may be candidates for ventriculostomy and external ventricular drainage. The management of intraventricular hemorrhage is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/55/6009?source=see_link\">",
"     \"Intraventricular hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Hemostatic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemostatic therapy offers the potential to improve outcome by stopping ongoing hemorrhage and preventing hemorrhage enlargement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29130?source=see_link&amp;anchor=H6#H6\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\", section on 'Hemorrhage enlargement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The agent that has been most studied for use in ICH is activated recombinant factor VIIa (rFVIIa), which promotes hemostasis at sites of vascular injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/105\">",
"     105",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/13/31962?source=see_link&amp;anchor=H3#H3\">",
"     \"Therapeutic uses of recombinant coagulation factor VIIa\", section on 'Mechanism of action'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While preliminary studies suggested that treatment with rFVIIa was safe and effective for ICH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/106,107\">",
"     106,107",
"    </a>",
"    ], results from the multicenter double-blind phase 3 clinical trial were disappointing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/108\">",
"     108",
"    </a>",
"    ]. The trial randomly assigned 841 patients with spontaneous ICH (confirmed by head CT scan within three hours of symptom onset) to receive either rFVIIa (20 or 80",
"    <span class=\"nowrap\">",
"     mcg/kg)",
"    </span>",
"    or placebo within four hours of symptom onset. Compared with placebo, treatment with rFVIIa was associated with a significant reduction in hematoma growth. However, rFVIIa treatment did not result in improvement in the primary outcome measures, death or severe disability at day 90.",
"   </p>",
"   <p>",
"    In contrast, the earlier multicenter phase 2B study evaluated 399 patients with spontaneous ICH and found that treatment significantly reduced the risk of severe disability or death compared with placebo at 90 days (absolute risk reduction of 16 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recombinant factor VIIa has a potential risk of serious side effects from activation of the coagulation system or thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/105\">",
"     105",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the phase 3 trial, the overall frequency of thromboembolic serious adverse events was similar among treatment groups, but the rate of arterial thromboembolic serious adverse events (myocardial infarction or cerebral infarction) was significantly higher in the group assigned to 80",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      when compared with placebo (8 versus 4 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/108\">",
"       108",
"      </a>",
"      ]. Similar findings were noted in an analysis of pooled data from three earlier randomized controlled trials of rFVIIa for spontaneous ICH, in which the rate of arterial thromboembolic serious adverse events was significantly increased in those assigned to high-dose rFVIIa (120 to 160",
"      <span class=\"nowrap\">",
"       mcg/kg)",
"      </span>",
"      compared with placebo (5.4 versus 1.7 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/109\">",
"       109",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Small open-label studies suggest that rFVIIa treatment for ICH is associated with increased rates of troponin elevation and myocardial infarction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/110\">",
"       110",
"      </a>",
"      ] and higher than expected rates of posthemorrhagic hydrocephalus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/111\">",
"       111",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/13/31962?source=see_link&amp;anchor=H25#H25\">",
"       \"Therapeutic uses of recombinant coagulation factor VIIa\", section on 'Safety issues'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the available data, we agree with current guidelines and conclusions of systematic reviews that recombinant factor VIIa treatment for acute ICH (not associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    use) is investigational and should not be used for treatment of ICH outside the context of a clinical trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/12,55,112\">",
"     12,55,112",
"    </a>",
"    ]. The use of factor VIIa for warfarin-associated ICH is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10298?source=see_link\">",
"     \"Management of warfarin-associated intracerebral hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Resumption of antiplatelet therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A common question is when patients can resume antiplatelet therapy after suffering an ICH. Our experience with the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    suggests that it is probably safe to resume therapy after the acute phase of ICH provided that blood pressure is well controlled and that the indication for antiplatelet treatment is sufficiently strong that the potential benefit outweighs the increase in risk of recurrent ICH.",
"   </p>",
"   <p>",
"    Unfortunately, there are limited data that specifically address this issue. Therefore, most decisions must be made by extrapolating from the limited data regarding antiplatelet therapy and the risk of primary ICH. The best available data comes from meta-analyses of randomized controlled trials; these suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    use is associated with an approximately 40 percent relative increase in the risk of initial ICH, which translates into a very small absolute increase in risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/113,114\">",
"     113,114",
"    </a>",
"    ].(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/57/8089?source=see_link&amp;anchor=H15#H15\">",
"     \"Anticoagulant and antiplatelet therapy in patients with an acute or prior intracerebral hemorrhage\", section on 'Aspirin and warfarin therapy'",
"    </a>",
"    .) In the setting of cerebral amyloid angiopathy, aspirin use may be associated with a greater risk of recurrent ICH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/115\">",
"     115",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37001?source=see_link&amp;anchor=H23#H23\">",
"     \"Cerebral amyloid angiopathy\", section on 'Avoidance of anticoagulants and antiplatelet agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    reduces the risk of ischemic stroke by 25 percent, this benefit is largely negated by the associated increased risk of recurrent ICH, which typically causes more disability than ischemic stroke. Therefore, we do not recommend aspirin or antiplatelets for those patients with only an \"average\" risk of recurrent ischemic stroke. What exactly constitutes \"average\" or \"above average\" risk is not certain, but we consider hypertension, diabetes, hypercholesterolemia, and the absence of heart disease to be markers of average risk. Atrial fibrillation, cardiomyopathy, large vessel extracranial and intracranial stenoses, and malignancy can be considered as markers for those with \"above average\" risk who may benefit from long-term antiplatelet therapy after ICH.",
"   </p>",
"   <p>",
"    We do not recommend resumption of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or antiplatelets for primary prevention of cardiovascular disease. In the few existing primary prevention studies, patients with any prior ICH were excluded. Such patients should avoid aspirin unless a compelling indication for aspirin use develops later on.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Timing and dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The timing of antiplatelet use after ICH is largely empiric. There is risk of rebleeding and hematoma expansion in the first several hours. At 10 days, rebleeding is unlikely. The",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    guidelines of 2006 state that antiplatelets should be discontinued for at least one to two weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some experts have argued that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    can be used safely as soon as 48 hours after ICH in those who require prophylaxis for venous thromboembolism. We agree, provided neuroimaging has demonstrated a stable ICH. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/57/8089?source=see_link&amp;anchor=H5#H5\">",
"     \"Anticoagulant and antiplatelet therapy in patients with an acute or prior intracerebral hemorrhage\", section on 'Prevention of VTE'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is used after ICH, we agree with others that a lower dose (30 to 160 mg daily) is both effective and safer than higher doses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/57/8089?source=see_link\">",
"     \"Anticoagulant and antiplatelet therapy in patients with an acute or prior intracerebral hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Resumption of anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The question of when to restart anticoagulation in patients at high risk for embolic events who have suffered an ICH has not been definitively answered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/71\">",
"     71",
"    </a>",
"    ]. For patients who require anticoagulation soon after a cerebral hemorrhage, the",
"    <span class=\"nowrap\">",
"     AHA/ASA",
"    </span>",
"    guidelines conclude that intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    may be safer than oral anticoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/71\">",
"     71",
"    </a>",
"    ]. In addition, the guidelines suggest that oral anticoagulants may be resumed three to four weeks after onset of the hemorrhage with rigorous monitoring and maintenance of INRs in the lower end of the therapeutic range. It is reasonable to consider risk factors for recurrent ICH when making",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    decisions regarding resumption of oral anticoagulation. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Recurrence'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Resumption of anticoagulation is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10298?source=see_link&amp;anchor=H19#H19\">",
"     \"Management of warfarin-associated intracerebral hemorrhage\", section on 'Resumption of anticoagulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Secondary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efforts to control blood pressure over the long term are likely to significantly reduce the risk of recurrent ICH. The potential magnitude of this effect was demonstrated in the PROGRESS trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/117\">",
"     117",
"    </a>",
"    ]. Among over 6000 patients with prior cerebrovascular events and a mean baseline blood pressure of",
"    <span class=\"nowrap\">",
"     147/86,",
"    </span>",
"    a modest reduction in blood pressure of",
"    <span class=\"nowrap\">",
"     9/4",
"    </span>",
"    mmHg decreased the rate of ICH by 50 percent (95% CI 26%-67%). In the subgroup of 611 patients with prior ICH, there was a similar 49 percent risk reduction (95% CI 18%-68%) for recurrent ICH. Guidelines published in 2010 suggest a goal blood pressure of",
"    <span class=\"nowrap\">",
"     &lt;140/90",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While treating hypertension is the most important step to reduce the risk of ICH, and probably recurrent ICH, stopping smoking, heavy alcohol use, and cocaine use are also recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are insufficient data to recommend general restrictions on the use of statin agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/55\">",
"     55",
"    </a>",
"    ]. A higher risk of ICH was observed in atorvastatin-treated patients in a secondary prevention trial of patients with ischemic cerebrovascular disease (SPARCL trial) and in the Heart Protection Study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/118,119\">",
"     118,119",
"    </a>",
"    ]. In the former study, the hazard ratio for ICH was higher for those who entered the study with hemorrhagic as opposed to ischemic stroke (4.1 versus 1.6) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/118\">",
"     118",
"    </a>",
"    ]. On the other hand, one case-control study found that statin use prior to ICH was associated with reduced mortality (OR 0.47) and increased probability of a favorable outcome (OR = 2.08) with similar results found in a meta-analysis of published studies of ICH and statin use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/120\">",
"     120",
"    </a>",
"    ]. In contrast, a previously published study had found that low LDL cholesterol levels on admission were associated with increased mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/121\">",
"     121",
"    </a>",
"    ]. Given the conflicting data, it seems to be reasonable to weigh the benefits and possible risks of statin therapy in individual patients who are at risk for ICH recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/122-124\">",
"     122-124",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Recurrence'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/34/22050?source=see_link\">",
"       \"Patient information: Hemorrhagic stroke (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/63/8180?source=see_link\">",
"       \"Patient information: Hemorrhagic stroke treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 30-day mortality from intracerebral hemorrhage ICH ranges from 35 to 52 percent. Among survivors, the prognosis for functional recovery depends upon the location of hemorrhage, size of the hematoma, level of consciousness, patient age, and overall medical health and condition. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prognostication for individual patients with acute ICH remains an uncertain science at best. Current guidelines suggest consideration of aggressive full care during the first 24 hours after intracerebral hemorrhage (ICH) onset and postponement of new do not resuscitate (DNR) orders during that time. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Limiting care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with acute ICH should be managed in an intensive care unit. All anticoagulant and antiplatelet drugs should be discontinued acutely, and anticoagulant effect should be reversed immediately with appropriate agents. Sources of fever should be treated. We suggest use of antipyretic medications to lower body temperature to normothermia in febrile patients. We suggest insulin treatment for elevated serum glucose &gt;185",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&gt;10.3",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'General management issues'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Reversal of anticoagulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevention of venous thromboembolism and deep venous thrombosis in patients with ICH is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/57/8089?source=see_link\">",
"       \"Anticoagulant and antiplatelet therapy in patients with an acute or prior intracerebral hemorrhage\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Initial management of elevated intracranial pressure (ICP) includes elevating the head of the bed to 30 degrees and use of analgesia and sedation. Suggested intravenous agents for sedation are",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"       propofol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"       etomidate",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"       midazolam",
"      </a>",
"      . Suggested agents for analgesia and antitussive effect are",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/9/3223?source=see_link\">",
"       alfentanil",
"      </a>",
"      .",
"      <br/>",
"      <br/>",
"      More aggressive therapies for reducing elevated ICP include osmotic diuretics (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      ), ventricular catheter drainage of cerebrospinal fluid, neuromuscular blockade, and hyperventilation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/56/32650/abstract/12\">",
"       12",
"      </a>",
"      ]. We suggest continuous monitoring of ICP and arterial blood pressure when using these aggressive therapies, with the goal of maintaining cerebral perfusion pressure above 70 mmHg. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Intracranial pressure control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Severe elevations in blood pressure may worsen ICH by representing a continued force for bleeding.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35544?source=see_link\">",
"       Labetalol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/61/42969?source=see_link\">",
"       nicardipine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/37/40536?source=see_link\">",
"       esmolol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/19/8505?source=see_link\">",
"       enalapril",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"       nitroprusside",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      are useful intravenous agents for controlling blood pressure. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Blood pressure control'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with systolic blood pressure (SBP) &gt;200 mmHg or mean arterial pressure (MAP) &gt;150 mmHg, we suggest aggressive reduction of blood pressure with continuous intravenous infusion of medication accompanied by blood pressure monitoring every five minutes.",
"     </li>",
"     <li>",
"      For patients with SBP &gt;180 mmHg or MAP &gt;130 mmHg and evidence or suspicion of elevated ICP, we suggest monitoring ICP and reducing blood pressure using intermittent or continuous intravenous medication to keep cerebral perfusion pressure in the range of 61 to 80 mmHg.",
"     </li>",
"     <li>",
"      For patients with SBP &gt;180 mmHg or MAP &gt;130 mmHg and no evidence or suspicion of elevated ICP, we suggest a modest reduction of blood pressure to a target MAP of 110 mmHg or target blood pressure of",
"      <span class=\"nowrap\">",
"       160/90",
"      </span>",
"      mmHg using intermittent or continuous intravenous medication accompanied by reexamination of the patient every 15 minutes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Appropriate intravenous antiepileptic treatment should be used to quickly control seizures for patients with ICH and clinical seizures. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Seizure prophylaxis and treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with cerebellar hemorrhages &gt;3 cm in diameter who are deteriorating or who have brainstem compression",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hydrocephalus due to ventricular obstruction, we recommend surgical removal of hemorrhage. Surgery for supratentorial ICH is controversial, and current guidelines suggest consideration of standard craniotomy only for those who have lobar clots within 1 cm of the surface. The routine evacuation of supratentorial ICH in the first 96 hours is not recommended. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recombinant factor VIIa treatment for acute ICH is investigational and should not be used for the treatment of ICH outside the context of a clinical trial. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Hemostatic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treating hypertension is the most important step to reduce the risk of ICH, and probably recurrent ICH. Stopping smoking, heavy alcohol use, and cocaine use are also recommended. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Secondary prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/1\">",
"      Anderson CS, Chakera TM, Stewart-Wynne EG, Jamrozik KD. Spectrum of primary intracerebral haemorrhage in Perth, Western Australia, 1989-90: incidence and outcome. J Neurol Neurosurg Psychiatry 1994; 57:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/2\">",
"      Counsell C, Boonyakarnukul S, Dennis M, et al. Primary intracerebral hemorrhage in the Oxford-shire community Stroke Project. Cerebrovasc Dis 1995; 5:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/3\">",
"      Broderick JP, Brott TG, Duldner JE, et al. Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. Stroke 1993; 24:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/4\">",
"      Fogelholm R, Murros K, Rissanen A, Avikainen S. Long term survival after primary intracerebral haemorrhage: a retrospective population based study. J Neurol Neurosurg Psychiatry 2005; 76:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/5\">",
"      Flaherty ML, Haverbusch M, Sekar P, et al. Long-term mortality after intracerebral hemorrhage. Neurology 2006; 66:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/6\">",
"      Sacco S, Marini C, Toni D, et al. Incidence and 10-year survival of intracerebral hemorrhage in a population-based registry. Stroke 2009; 40:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/7\">",
"      Zia E, Engstr&ouml;m G, Svensson PJ, et al. Three-year survival and stroke recurrence rates in patients with primary intracerebral hemorrhage. Stroke 2009; 40:3567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/8\">",
"      van Asch CJ, Luitse MJ, Rinkel GJ, et al. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol 2010; 9:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/9\">",
"      Franke CL, van Swieten JC, Algra A, van Gijn J. Prognostic factors in patients with intracerebral haematoma. J Neurol Neurosurg Psychiatry 1992; 55:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/10\">",
"      Daverat P, Castel JP, Dartigues JF, Orgogozo JM. Death and functional outcome after spontaneous intracerebral hemorrhage. A prospective study of 166 cases using multivariate analysis. Stroke 1991; 22:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/11\">",
"      Tuhrim S, Dambrosia JM, Price TR, et al. Intracerebral hemorrhage: external validation and extension of a model for prediction of 30-day survival. Ann Neurol 1991; 29:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/12\">",
"      Broderick J, Connolly S, Feldmann E, et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke 2007; 38:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/13\">",
"      Stein M, Misselwitz B, Hamann GF, et al. Intracerebral hemorrhage in the very old: future demographic trends of an aging population. Stroke 2012; 43:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/14\">",
"      Saloheimo P, Ahonen M, Juvela S, et al. Regular aspirin-use preceding the onset of primary intracerebral hemorrhage is an independent predictor for death. Stroke 2006; 37:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/15\">",
"      van Beijnum J, Lovelock CE, Cordonnier C, et al. Outcome after spontaneous and arteriovenous malformation-related intracerebral haemorrhage: population-based studies. Brain 2009; 132:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/16\">",
"      Beslow LA, Licht DJ, Smith SE, et al. Predictors of outcome in childhood intracerebral hemorrhage: a prospective consecutive cohort study. Stroke 2010; 41:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/17\">",
"      Saloheimo P, Lapp TM, Juvela S, Hillbom M. The impact of functional status at three months on long-term survival after spontaneous intracerebral hemorrhage. Stroke 2006; 37:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/18\">",
"      Jordan LC, Kleinman JT, Hillis AE. Intracerebral hemorrhage volume predicts poor neurologic outcome in children. Stroke 2009; 40:1666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/19\">",
"      Rodriguez-Luna D, Rubiera M, Ribo M, et al. Ultraearly hematoma growth predicts poor outcome after acute intracerebral hemorrhage. Neurology 2011; 77:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/20\">",
"      Davis SM, Broderick J, Hennerici M, et al. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology 2006; 66:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/21\">",
"      Dowlatshahi D, Demchuk AM, Flaherty ML, et al. Defining hematoma expansion in intracerebral hemorrhage: relationship with patient outcomes. Neurology 2011; 76:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/22\">",
"      Portenoy RK, Lipton RB, Berger AR, et al. Intracerebral haemorrhage: a model for the prediction of outcome. J Neurol Neurosurg Psychiatry 1987; 50:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/23\">",
"      Young WB, Lee KP, Pessin MS, et al. Prognostic significance of ventricular blood in supratentorial hemorrhage: a volumetric study. Neurology 1990; 40:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/24\">",
"      Lisk DR, Pasteur W, Rhoades H, et al. Early presentation of hemispheric intracerebral hemorrhage: prediction of outcome and guidelines for treatment allocation. Neurology 1994; 44:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/25\">",
"      Tuhrim S, Horowitz DR, Sacher M, Godbold JH. Volume of ventricular blood is an important determinant of outcome in supratentorial intracerebral hemorrhage. Crit Care Med 1999; 27:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/26\">",
"      Hallevi H, Albright KC, Aronowski J, et al. Intraventricular hemorrhage: Anatomic relationships and clinical implications. Neurology 2008; 70:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/27\">",
"      Staykov D, Volbers B, Wagner I, et al. Prognostic significance of third ventricle blood volume in intracerebral haemorrhage with severe ventricular involvement. J Neurol Neurosurg Psychiatry 2011; 82:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/28\">",
"      Mayer SA, Sacco RL, Shi T, Mohr JP. Neurologic deterioration in noncomatose patients with supratentorial intracerebral hemorrhage. Neurology 1994; 44:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/29\">",
"      Leira R, D&aacute;valos A, Silva Y, et al. Early neurologic deterioration in intracerebral hemorrhage: predictors and associated factors. Neurology 2004; 63:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/30\">",
"      Qureshi AI, Safdar K, Weil J, et al. Predictors of early deterioration and mortality in black Americans with spontaneous intracerebral hemorrhage. Stroke 1995; 26:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/31\">",
"      Flemming KD, Wijdicks EF, St Louis EK, Li H. Predicting deterioration in patients with lobar haemorrhages. J Neurol Neurosurg Psychiatry 1999; 66:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/32\">",
"      Arima H, Wang JG, Huang Y, et al. Significance of perihematomal edema in acute intracerebral hemorrhage: the INTERACT trial. Neurology 2009; 73:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/33\">",
"      Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke 1995; 26:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/34\">",
"      Rosand J, Eckman MH, Knudsen KA, et al. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004; 164:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/35\">",
"      Cucchiara B, Messe S, Sansing L, et al. Hematoma growth in oral anticoagulant related intracerebral hemorrhage. Stroke 2008; 39:2993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/36\">",
"      Toyoda K, Okada Y, Minematsu K, et al. Antiplatelet therapy contributes to acute deterioration of intracerebral hemorrhage. Neurology 2005; 65:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/37\">",
"      Naidech AM, Bernstein RA, Levasseur K, et al. Platelet activity and outcome after intracerebral hemorrhage. Ann Neurol 2009; 65:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/38\">",
"      Naidech AM, Jovanovic B, Liebling S, et al. Reduced platelet activity is associated with early clot growth and worse 3-month outcome after intracerebral hemorrhage. Stroke 2009; 40:2398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/39\">",
"      Foerch C, Sitzer M, Steinmetz H, Neumann-Haefelin T. Pretreatment with antiplatelet agents is not independently associated with unfavorable outcome in intracerebral hemorrhage. Stroke 2006; 37:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/40\">",
"      Nilsson OG, Lindgren A, Brandt L, S&auml;veland H. Prediction of death in patients with primary intracerebral hemorrhage: a prospective study of a defined population. J Neurosurg 2002; 97:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/41\">",
"      Flibotte JJ, Hagan N, O'Donnell J, et al. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 2004; 63:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/42\">",
"      Brott T, Broderick J, Kothari R, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 1997; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/43\">",
"      Sansing LH, Messe SR, Cucchiara BL, et al. Prior antiplatelet use does not affect hemorrhage growth or outcome after ICH. Neurology 2009; 72:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/44\">",
"      Thompson BB, B&eacute;jot Y, Caso V, et al. Prior antiplatelet therapy and outcome following intracerebral hemorrhage: a systematic review. Neurology 2010; 75:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/45\">",
"      Hemphill JC 3rd, Bonovich DC, Besmertis L, et al. The ICH score: a simple, reliable grading scale for intracerebral hemorrhage. Stroke 2001; 32:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/46\">",
"      Cheung RT, Zou LY. Use of the original, modified, or new intracerebral hemorrhage score to predict mortality and morbidity after intracerebral hemorrhage. Stroke 2003; 34:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/47\">",
"      Godoy DA, Pi&ntilde;ero G, Di Napoli M. Predicting mortality in spontaneous intracerebral hemorrhage: can modification to original score improve the prediction? Stroke 2006; 37:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/48\">",
"      Hemphill JC 3rd, Farrant M, Neill TA Jr. Prospective validation of the ICH Score for 12-month functional outcome. Neurology 2009; 73:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/49\">",
"      Muir KW, Weir CJ, Murray GD, et al. Comparison of neurological scales and scoring systems for acute stroke prognosis. Stroke 1996; 27:1817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/50\">",
"      Becker KJ, Baxter AB, Cohen WA, et al. Withdrawal of support in intracerebral hemorrhage may lead to self-fulfilling prophecies. Neurology 2001; 56:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/51\">",
"      Hemphill JC 3rd, Newman J, Zhao S, Johnston SC. Hospital usage of early do-not-resuscitate orders and outcome after intracerebral hemorrhage. Stroke 2004; 35:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/52\">",
"      Zahuranec DB, Brown DL, Lisabeth LD, et al. Early care limitations independently predict mortality after intracerebral hemorrhage. Neurology 2007; 68:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/53\">",
"      Zahuranec DB, Morgenstern LB, S&aacute;nchez BN, et al. Do-not-resuscitate orders and predictive models after intracerebral hemorrhage. Neurology 2010; 75:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/54\">",
"      Creutzfeldt CJ, Becker KJ, Weinstein JR, et al. Do-not-attempt-resuscitation orders and prognostic models for intraparenchymal hemorrhage. Crit Care Med 2011; 39:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/55\">",
"      Morgenstern LB, Hemphill JC 3rd, Anderson C, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2010; 41:2108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/56\">",
"      Bar B, Hemphill JC 3rd. Charlson comorbidity index adjustment in intracerebral hemorrhage. Stroke 2011; 42:2944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/57\">",
"      Passero S, Ciacci G, Ulivelli M. The influence of diabetes and hyperglycemia on clinical course after intracerebral hemorrhage. Neurology 2003; 61:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/58\">",
"      Fogelholm R, Murros K, Rissanen A, Avikainen S. Admission blood glucose and short term survival in primary intracerebral haemorrhage: a population based study. J Neurol Neurosurg Psychiatry 2005; 76:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/59\">",
"      Appelboom G, Piazza MA, Hwang BY, et al. Severity of intraventricular extension correlates with level of admission glucose after intracerebral hemorrhage. Stroke 2011; 42:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/60\">",
"      B&eacute;jot Y, Aboa-Eboul&eacute; C, Hervieu M, et al. The deleterious effect of admission hyperglycemia on survival and functional outcome in patients with intracerebral hemorrhage. Stroke 2012; 43:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/61\">",
"      Balami JS, Buchan AM. Complications of intracerebral haemorrhage. Lancet Neurol 2012; 11:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/62\">",
"      Rodriguez-Luna D, Rubiera M, Ribo M, et al. Serum low-density lipoprotein cholesterol level predicts hematoma growth and clinical outcome after acute intracerebral hemorrhage. Stroke 2011; 42:2447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/63\">",
"      Lee SH, Kim BJ, Ryu WS, et al. White matter lesions and poor outcome after intracerebral hemorrhage: a nationwide cohort study. Neurology 2010; 74:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/64\">",
"      Di Napoli M, Godoy DA, Campi V, et al. C-reactive protein level measurement improves mortality prediction when added to the spontaneous intracerebral hemorrhage score. Stroke 2011; 42:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/65\">",
"      Menon RS, Burgess RE, Wing JJ, et al. Predictors of highly prevalent brain ischemia in intracerebral hemorrhage. Ann Neurol 2012; 71:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/66\">",
"      Garg RK, Liebling SM, Maas MB, et al. Blood pressure reduction, decreased diffusion on MRI, and outcomes after intracerebral hemorrhage. Stroke 2012; 43:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/67\">",
"      Chen ST, Chiang CY, Hsu CY, et al. Recurrent hypertensive intracerebral hemorrhage. Acta Neurol Scand 1995; 91:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/68\">",
"      Bae H, Jeong D, Doh J, et al. Recurrence of bleeding in patients with hypertensive intracerebral hemorrhage. Cerebrovasc Dis 1999; 9:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/69\">",
"      Hanger HC, Wilkinson TJ, Fayez-Iskander N, Sainsbury R. The risk of recurrent stroke after intracerebral haemorrhage. J Neurol Neurosurg Psychiatry 2007; 78:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/70\">",
"      Manno EM, Atkinson JL, Fulgham JR, Wijdicks EF. Emerging medical and surgical management strategies in the evaluation and treatment of intracerebral hemorrhage. Mayo Clin Proc 2005; 80:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/71\">",
"      Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011; 42:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/72\">",
"      Genewein U, Haeberli A, Straub PW, Beer JH. Rebound after cessation of oral anticoagulant therapy: the biochemical evidence. Br J Haematol 1996; 92:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/73\">",
"      Poungvarin N, Bhoopat W, Viriyavejakul A, et al. Effects of dexamethasone in primary supratentorial intracerebral hemorrhage. N Engl J Med 1987; 316:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/74\">",
"      Helbok R, Kurtz P, Schmidt JM, et al. Effect of mannitol on brain metabolism and tissue oxygenation in severe haemorrhagic stroke. J Neurol Neurosurg Psychiatry 2011; 82:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/75\">",
"      Dorman HR, Sondheimer JH, Cadnapaphornchai P. Mannitol-induced acute renal failure. Medicine (Baltimore) 1990; 69:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/76\">",
"      Schwab S, Spranger M, Schwarz S, Hacke W. Barbiturate coma in severe hemispheric stroke: useful or obsolete? Neurology 1997; 48:1608.",
"     </a>",
"    </li>",
"    <li>",
"     Neurological and Neurosurgical Intensive Care. Ropper, AH (Ed), Raven Press, New York 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/78\">",
"      Adams RE, Diringer MN. Response to external ventricular drainage in spontaneous intracerebral hemorrhage with hydrocephalus. Neurology 1998; 50:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/79\">",
"      Schade RP, Schinkel J, Visser LG, et al. Bacterial meningitis caused by the use of ventricular or lumbar cerebrospinal fluid catheters. J Neurosurg 2005; 102:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/80\">",
"      Dunn LT. Raised intracranial pressure. J Neurol Neurosurg Psychiatry 2002; 73 Suppl 1:i23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/81\">",
"      Lozier AP, Sciacca RR, Romagnoli MF, Connolly ES Jr. Ventriculostomy-related infections: a critical review of the literature. Neurosurgery 2002; 51:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/82\">",
"      Holloway KL, Barnes T, Choi S, et al. Ventriculostomy infections: the effect of monitoring duration and catheter exchange in 584 patients. J Neurosurg 1996; 85:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/83\">",
"      Ohwaki K, Yano E, Nagashima H, et al. Blood pressure management in acute intracerebral hemorrhage: relationship between elevated blood pressure and hematoma enlargement. Stroke 2004; 35:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/84\">",
"      Qureshi AI. Significance of lesions with decreased diffusion on MRI in patients with intracerebral hemorrhage. Stroke 2012; 43:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/85\">",
"      Anderson CS, Huang Y, Wang JG, et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurol 2008; 7:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/86\">",
"      Anderson CS, Huang Y, Arima H, et al. Effects of early intensive blood pressure-lowering treatment on the growth of hematoma and perihematomal edema in acute intracerebral hemorrhage: the Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT). Stroke 2010; 41:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/87\">",
"      Qureshi AI, Mohammad YM, Yahia AM, et al. A prospective multicenter study to evaluate the feasibility and safety of aggressive antihypertensive treatment in patients with acute intracerebral hemorrhage. J Intensive Care Med 2005; 20:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/88\">",
"      Qureshi AI, Palesch YY, Martin R, et al. Effect of systolic blood pressure reduction on hematoma expansion, perihematomal edema, and 3-month outcome among patients with intracerebral hemorrhage: results from the antihypertensive treatment of acute cerebral hemorrhage study. Arch Neurol 2010; 67:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/89\">",
"      Kuramatsu JB, Sauer R, Mauer C, et al. Correlation of age and haematoma volume in patients with spontaneous lobar intracerebral haemorrhage. J Neurol Neurosurg Psychiatry 2011; 82:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/90\">",
"      Naidech AM, Garg RK, Liebling S, et al. Anticonvulsant use and outcomes after intracerebral hemorrhage. Stroke 2009; 40:3810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/91\">",
"      Mess&eacute; SR, Sansing LH, Cucchiara BL, et al. Prophylactic antiepileptic drug use is associated with poor outcome following ICH. Neurocrit Care 2009; 11:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/92\">",
"      Ott KH, Kase CS, Ojemann RG, Mohr JP. Cerebellar hemorrhage: diagnosis and treatment. A review of 56 cases. Arch Neurol 1974; 31:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/93\">",
"      Hankey GJ, Hon C. Surgery for primary intracerebral hemorrhage: is it safe and effective? A systematic review of case series and randomized trials. Stroke 1997; 28:2126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/94\">",
"      Batjer HH, Reisch JS, Allen BC, et al. Failure of surgery to improve outcome in hypertensive putaminal hemorrhage. A prospective randomized trial. Arch Neurol 1990; 47:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/95\">",
"      Morgenstern LB, Demchuk AM, Kim DH, et al. Rebleeding leads to poor outcome in ultra-early craniotomy for intracerebral hemorrhage. Neurology 2001; 56:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/96\">",
"      Minematsu K. Evacuation of intracerebral hematoma is likely to be beneficial. Stroke 2003; 34:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/97\">",
"      Hankey GJ. Evacuation of intracerebral hematoma is likely to be beneficial--against. Stroke 2003; 34:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/98\">",
"      Donnan GA, Davis SM. Surgery for intracerebral hemorrhage: an evidence-poor zone. Stroke 2003; 34:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/99\">",
"      Mendelow AD, Gregson BA, Fernandes HM, et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet 2005; 365:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/100\">",
"      Nakano T, Ohkuma H. Surgery versus conservative treatment for intracerebral haemorrhage--is there an end to the long controversy? Lancet 2005; 365:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/101\">",
"      Zuccarello M, Brott T, Derex L, et al. Early surgical treatment for supratentorial intracerebral hemorrhage: a randomized feasibility study. Stroke 1999; 30:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/102\">",
"      Brown DL, Morgenstern LB. Stopping the bleeding in intracerebral hemorrhage. N Engl J Med 2005; 352:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/103\">",
"      Broderick JP. The STICH trial: what does it tell us and where do we go from here? Stroke 2005; 36:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/104\">",
"      Prasad K, Mendelow AD, Gregson B. Surgery for primary supratentorial intracerebral haemorrhage. Cochrane Database Syst Rev 2008; :CD000200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/105\">",
"      O'Connell KA, Wood JJ, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/106\">",
"      Mayer SA, Brun NC, Broderick J, et al. Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage. Stroke 2005; 36:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/107\">",
"      Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005; 352:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/108\">",
"      Mayer SA, Brun NC, Begtrup K, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008; 358:2127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/109\">",
"      Diringer MN, Skolnick BE, Mayer SA, et al. Risk of thromboembolic events in controlled trials of rFVIIa in spontaneous intracerebral hemorrhage. Stroke 2008; 39:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/110\">",
"      Sugg RM, Gonzales NR, Matherne DE, et al. Myocardial injury in patients with intracerebral hemorrhage treated with recombinant factor VIIa. Neurology 2006; 67:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/111\">",
"      Subramaniam S, Demchuk AM, Watson T, et al. Unexpected posthemorrhagic hydrocephalus in patients treated with rFVIIa. Neurology 2006; 67:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/112\">",
"      Al-Shahi Salman R. Haemostatic drug therapies for acute spontaneous intracerebral haemorrhage. Cochrane Database Syst Rev 2009; :CD005951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/113\">",
"      He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA 1998; 280:1930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/114\">",
"      Hart RG, Halperin JL, McBride R, et al. Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. Arch Neurol 2000; 57:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/115\">",
"      Biffi A, Halpin A, Towfighi A, et al. Aspirin and recurrent intracerebral hemorrhage in cerebral amyloid angiopathy. Neurology 2010; 75:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/116\">",
"      Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006; 37:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/117\">",
"      Chapman N, Huxley R, Anderson C, et al. Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke 2004; 35:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/118\">",
"      Goldstein LB, Amarenco P, Szarek M, et al. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 2008; 70:2364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/119\">",
"      Collins R, Armitage J, Parish S, et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/120\">",
"      Biffi A, Devan WJ, Anderson CD, et al. Statin use and outcome after intracerebral hemorrhage: case-control study and meta-analysis. Neurology 2011; 76:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/121\">",
"      Ram&iacute;rez-Moreno JM, Casado-Naranjo I, Portilla JC, et al. Serum cholesterol LDL and 90-day mortality in patients with intracerebral hemorrhage. Stroke 2009; 40:1917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/122\">",
"      Westover MB, Bianchi MT, Eckman MH, Greenberg SM. Statin use following intracerebral hemorrhage: a decision analysis. Arch Neurol 2011; 68:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/123\">",
"      Goldstein LB. Statins after intracerebral hemorrhage: to treat or not to treat. Arch Neurol 2011; 68:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/56/32650/abstract/124\">",
"      Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009; 8:453.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1084 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-27.109.116.13-BBD231414A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_56_32650=[""].join("\n");
var outline_f31_56_32650=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mortality and functional outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Initial ICH volume and level of consciousness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Hematoma growth",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Intraventricular extension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Early neurologic deterioration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Preceding antithrombotic use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3373984\">",
"      Oral anticoagulants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3374003\">",
"      Antiplatelets",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - ICH score",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Limiting care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Other factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      General management issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Reversal of anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Intracranial pressure control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Aggressive measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Blood pressure control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Seizure prophylaxis and treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2514292\">",
"      Intraventricular hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Hemostatic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Resumption of antiplatelet therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Timing and dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Resumption of anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1084\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1084|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/62/29676\" title=\"table 1\">",
"      Glasgow coma scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/32/23051\" title=\"table 2\">",
"      Modified Rankin scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/33/40477\" title=\"table 3\">",
"      NIH Stroke Scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/57/8089?source=related_link\">",
"      Anticoagulant and antiplatelet therapy in patients with an acute or prior intracerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37001?source=related_link\">",
"      Cerebral amyloid angiopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20586?source=related_link\">",
"      Clinical and laboratory aspects of platelet transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32451?source=related_link\">",
"      Complications of mannitol therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=related_link\">",
"      Evaluation and management of elevated intracranial pressure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/29/33242?source=related_link\">",
"      Initial assessment and management of acute stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/55/6009?source=related_link\">",
"      Intraventricular hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10298?source=related_link\">",
"      Management of warfarin-associated intracerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/34/22050?source=related_link\">",
"      Patient information: Hemorrhagic stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/63/8180?source=related_link\">",
"      Patient information: Hemorrhagic stroke treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/29/15833?source=related_link\">",
"      Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/29/41430?source=related_link\">",
"      Serum osmolal gap",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29130?source=related_link\">",
"      Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/13/31962?source=related_link\">",
"      Therapeutic uses of recombinant coagulation factor VIIa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/44/43720?source=related_link\">",
"      Use of neuromuscular blocking medications in critically ill patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_56_32651="Campisi staging system for lymphedema";
var content_f31_56_32651=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F81911&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F81911&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Campisi staging system for lymphedema",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Stage I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A.\"Latent\" lymphedema, without clinical evidence of edema, but with impaired lymph transport capacity (provable by lymphoscintigraphy) and with initial immuno-histochemical alterations of lymph nodes, lymph vessels and extracellular matrix.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B.\"Initial\" lymphedema, totally or partially decreasing by rest and draining position, with worsening impairment of lymph transport capacity and of immuno-histochemical alterations of lymph collectors, nodes and extracellular matrix.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Stage II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A. \"Increasing\" lymphedema, with vanishing lymph transport capacity, relapsing lymphangitic attacks, fibroindurative skin changes, and developing disability.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. \"Column shaped\" limb fibrolymphedema, with lymphostatic skin changes, suppressed lymph transport capacity and worsening disability.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Stage III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A. Properly called \"elephantiasis\", with scleroindurative pachydermitis, papillomatous lymphostatic verrucosis, no lymph transport capacity and life-threatening disability.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B. \"Extreme elephantiasis\" with total disability.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Campisi C, Campisis C, Accogli S, et al. Lymphedema staging and surgical indications in geriatric age. BMC Geriatrics 2010; 10(Suppl 1):A50. Copyright &copy; 2010.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_56_32651=[""].join("\n");
var outline_f31_56_32651=null;
var title_f31_56_32652="Joint exam child";
var content_f31_56_32652=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55468&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55468&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Joint examination of a child",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Lower limbs: patient lying down",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       1. Inspection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       a. Symmetry",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       b. Size (limb length, muscle wasting, joint enlargement)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       c. Skin (scars, color, warmth, vascular pattern)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       d. Postural deformity (flexion, valgus)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       2. Palpation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       a. Soles of feet, insertions of tendon into bone (enthesitis)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       b. Joint margins (metatarsal squeeze, anterior ankle, medial knee)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       c. Palpate joint enlargement (is it bony, soft tissue or fluid?)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. Active movement: curl toes, dorsiflex ankles, bend knees and hips, watch for subtle compensatory movements",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. Passive movement: joint range of movement (note both increased range [hypermobility] and reduced range [restriction]: forefoot and hindfoot inversion/eversion, relaxed passive extension of knees, internal rotation of hips (knees and hips flexed to 90 percent): watch for subtle guarding and compensatory movements",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Upper limbs: patient sitting up",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1. Inspection similar to evaluation for lower limbs: symmetry, size, scars, wasting, enlargement, nails",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Palpation: joint margins (metacarpal squeeze, dorsal wrist, anterior glenohumeral), palpate bony enlargements, warmth",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. Active movement: finger extension, fist, tuck, wrist extension (prayer position), arms straight up then behind head then behind lower back, neck extension and rotation (chin to shoulder), beware compensatory movements (especially elbow lift on wrist flexion, lateral flexion of spine on shoulder abduction)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. Passive movement: joint range of movement, wrist flexion and extension (watch for subtle guarding and compensatory movements)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Axial skeleton: patient standing up",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1. Inspect symmetry from behind: especially posterior ankles, pelvic position, spine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Spinal movements: scoliosis, lumbar mobility (lumbar curve on forward flexion, lumbar pain on hyperextension), cervical spine extension and lateral rotation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. Gait: normal, tip toes, heels",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. Muscle power: Gowers test, Trendelenberg gait",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5. Temporo-mandibular joint",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6. Sacroiliac joints: direct palpation",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Yukiko Kimura and TR Southwood.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_56_32652=[""].join("\n");
var outline_f31_56_32652=null;
var title_f31_56_32653="Sample ROC curve";
var content_f31_56_32653=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F82175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F82175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Receiver operating characteristic curve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 333px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The receiver operating characteristic curve (ROC) plots sensitivity against 1- specificity (ie, the false positive rate). Cutoff values for the diagnostic test vary along the length of the black curve, reflecting the interchange between sensitivity and specificity. The area under the ROC curve represents the accuracy of the test. A test that performs no better than chance would be represented by a straight line (red line) with an area under the ROC of 0.5. A near perfect test would have a rectangular configuration (blue line) with an area under the ROC approaching 1.00.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_56_32653=[""].join("\n");
var outline_f31_56_32653=null;
var title_f31_56_32654="BTS diving guidelines a";
var content_f31_56_32654=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73880%7EEM%2F54026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73880%7EEM%2F54026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of key points and recommendations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        The diving environment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diving is an arduous underwater activity in which environmental conditions affect bodily structure and function.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For",
"every 10 meters descent in sea water, ambient pressure increases by 100",
"kPa, equivalent to 1 atmosphere (1 bar). The volume of a given mass of",
"gas changes inversely in proportion to pressure. The gas in bodily",
"cavities such as the lungs, sinuses, middle ear and intestine is",
"therefore subject to compression during descent and expansion during",
"ascent. This may lead to tissue damage.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Partial pressure of",
"gases increases in direct proportion to the increase in ambient",
"pressure. Greater quantities of inert gas, mainly nitrogen, therefore",
"dissolve in tissues at depth and come out of solution on ascent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The density of inhaled gas increases with pressure, restricting breathing.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immersion displaces blood from the periphery into the thorax, reducing lung volume.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Work of breathing",
"increases due to a combination of increased gas density, increased",
"hydrostatic pressure, and altered respiratory mechanics.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The underwater breathing apparatus adds dead space and increases resistance to breathing.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        During diving, carbon dioxide retention may result from the above listed effects on the body.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Potential risks of diving",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        General risks: panic, hypothermia, physical trauma, and drowning.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Equipment/technique",
"problems: hypoxia, hyperoxia, or poisoning by inappropriate gas",
"mixtures or contaminant gases may result from equipment malfunction or",
"poor dive planning. A",
"malfunctioning respiratory regulator may result in aspiration.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Barotrauma:",
"is caused by compression or expansion of gas filled spaces during",
"descent or ascent, respectively. Compression of the lungs during",
"descent may lead to alveolar exudation",
"and haemorrhage. Expansion of the lungs during ascent may cause lung",
"rupture leading to pneumothorax, pneumomediastinum, and arterial gas",
"embolism.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decompression illness:",
"may occur when gas, which has dissolved in tissues while at depth,",
"comes out of solution as bubbles. Clinical manifestations vary, the",
"most severe being cardiorespiratory and neurological.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loss of buoyancy control: is a cause of many accidents, usually when it leads to rapid uncontrolled ascent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        It is also essential to consider comorbidities such as",
"diabetes and epilepsy which may influence capability for diving but are",
"outside the scope of this document.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        The physician should bear the following general concepts in mind when assessing respiratory fitness to dive:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        The subject may be required to swim in strong currents.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        The subject may be required to rescue a companion (dive buddy) in the event of an emergency.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        The diving environment is associated with a risk of lung rupture.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        The gas breathed by the diver may be very cold.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Buoyancy",
"control is essential and requires training, experience, and use of",
"appropriate equipment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The following recommendations are therefore made.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Assessment of respiratory fitness to dive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In the history,",
"particular attention should be paid to current respiratory symptoms,",
"previous history of lung disease including childhood history, previous",
"trauma to the chest, and previous episodes of pneumothorax.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory system examination should be performed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Forced expiratory",
"volume in 1 second (FEV1), forced vital capacity (FVC), and peak",
"expiratory flow rate (PEF) should be measured. FEV1 and PEF should",
"normally be greater than 80% of predicted and the FEV1/FVC ratio",
"greater than 70 percent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Routine chest",
"radiography is not considered necessary in asymptomatic subjects with",
"no significant respiratory history and normal examination findings.",
"However, all professional divers, including recreational divers, who",
"plan to work as instructors are recommended by the Health and Safety",
"Executive to undergo chest radiography.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest radiography",
"is appropriate if there is a previous history of any significant",
"respiratory illness - for example, pleurisy, pneumonia, recurrent",
"respiratory infections, sarcoidosis, chest surgery or trauma,",
"pneumothorax - and those with current respiratory symptoms and/or",
"abnormal examination findings.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Routine measurement",
"of the expiratory flow-volume loop, exercise testing, or bronchial",
"provocation testing are not considered necessary although these tests",
"may be useful in specific cases.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thoracic CT",
"scanning, which has greater sensitivity than standard chest radiography",
"to detect lung structural abnormality, may be useful in specific areas.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from Thorax, British Thoracic Society guidelines on respiratory aspects of fitness for diving, volume 58, pages 3-13, Copyright &copy; 2003, with permission from&nbsp;BMJ Publishing Group Ltd.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of key points and recommendations (continued)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Recommendations on specific respiratory conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lung bullae or cysts increase risk of barotrauma and are contraindications to diving.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Previous",
"spontaneous pneumothorax is a contraindication unless treated by",
"bilateral surgical pleurectomy and associated with normal lung function",
"and thoracic CT scan performed after surgery.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Subjects with asthma should be advised not to dive if they have wheeze precipitated by exercise, cold, or emotion.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"1\">",
"        Subjects with asthma may be permitted to dive if, with or without",
"regular inhaled anti-inflammatory agents (step 2 of the BTS",
"guidelines), they:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Are free of asthma symptoms;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Have normal spirometry (FEV1&gt;80 percent predicted and FEV1/VC ratio &gt;70 percent predicted); and",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Have a negative exercise test (&lt;15 percent fall in FEV1 after exercise).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Subjects with",
"asthma should monitor their asthma with regular twice daily peak flow",
"measurement and should refrain from diving if they have:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Active asthma - that is, symptoms requiring relief medication in the 48 hours preceding the dive;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        An increased peak flow variability (more than 20 percent diurnal variation).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        COPD",
"carries a theoretical increased risk of barotrauma and reduced exercise",
"tolerance. Subjects will probably be advised against diving on the",
"basis of reduced pulmonary function (FEV1 &lt;80 percent predicted).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Sarcoidosis has been associated with pulmonary barotrauma. Diving is",
"contraindicated in subjects who have active sarcoidosis. Those in whom",
"sarcoidosis has resolved should have normal chest radiography and",
"pulmonary function testing before being advised that they may proceed",
"with diving.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tuberculosis is a",
"potentially transmissible disease that may cause residual impairment of",
"lung structure and function. A subject with active tuberculosis should",
"not dive. After curative treatment they may dive if lung function and",
"chest radiograph are normal.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Cystic",
"fibrosis is often associated with abnormal pulmonary function and",
"increased risk of pneumothorax. Diving is contraindicated in those",
"patients who have pulmonary involvement.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fibrotic lung",
"disease reduces lung compliance and impairs gas transfer. Diving is",
"therefore contraindicated in subjects who have fibrotic lung disease.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Long term effects of diving on the lung",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Divers",
"tend to have large lung volumes with proportionately greater increases",
"in vital capacity than in FEV1. This may be attributable in part to the",
"effects of repeatedly breathing dense gas through increased resistances.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Divers may have reduced expiratory flow rates at low lung volumes, possibly reflecting small airway disease.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vital capacity of divers may decline with age at an increased rate.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Saturation diving causes a fall in carbon monoxide transfer which, once",
"the dive is completed, gradually returns to pre-dive values.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Sources of specialist advice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        In the United Kingdom, advice on sports diving",
"may be sought from the medical referees of the British Sub Aqua Club,",
"the Scottish Sub Aqua Club, or the Sub Aqua Association. Information is",
"available on the UK Sport Diving Medical Diving Committee website",
"(file://ww.uksdmc.co.uk). The Royal Navy Institute of Naval Medicine is",
"also willing to discuss cases with both divers and physicians.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        The Health and Safety Executive (HSE) is",
"responsible for commercial diving policy and regulation. Individuals",
"who are diving at work require a current HSE certificate of fitness to",
"dive following examination by an approved medical examiner of divers.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from Thorax, British Thoracic Society guidelines on respiratory aspects of fitness for diving, volume 58, pages 3-13, Copyright &copy; 2003, with permission from&nbsp;BMJ Publishing Group Ltd.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_56_32654=[""].join("\n");
var outline_f31_56_32654=null;
var title_f31_56_32655="Trigger finger injection";
var content_f31_56_32655=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F69701&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F69701&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Injection for flexor tenosynovitis (trigger finger)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The hand is placed flat with the palm up and the fingers outstretched. The proximal volar crease of the finger or the distal volar crease over the metacarpophalangeal (MP) joint of the thumb is identified. The point of entry for the finger is just proximal to the first volar crease in the midline. The point of entry for the thumb is at the distal volar crease in the midline. Ethyl chloride is sprayed on the skin for anesthesia. A 5/8 inch 25 gauge needle is inserted to a depth of 1/4 to 3/8 inch for trigger finger and 1/8 to 1/4 inch for trigger thumb. The needle is advanced down to the firm resistance of the flexor tendon, a rubbery sensation. The needle is held flush against the tendon, utilizing just the weight of the syringe. Without advancing the needle, 1/2 mL of lidocaine is injected for an anesthetic block for diagnostic purposes. For therapeutic injection, 1/4 mL of methylprednisolone (80 mg/mL) is injected in addition to lidocaine.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_56_32655=[""].join("\n");
var outline_f31_56_32655=null;
